> top > docs > PMC:3245220 > spans > 13205-15644 > annotations

PMC:3245220 / 13205-15644 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T6716 59-64 P09603 denotes M-CSF
T6717 61-64 P04141 denotes CSF
T6718 160-165 P09603 denotes M-CSF
T6719 162-165 P04141 denotes CSF
T6720 263-272 P42574 denotes caspase-3
T6721 340-345 P09603 denotes M-CSF
T6722 342-345 P04141 denotes CSF
T6723 460-465 P09603 denotes M-CSF
T6724 462-465 P04141 denotes CSF
T6725 475-484 P42574 denotes caspase-3
T6726 591-596 P09603 denotes M-CSF
T6727 593-596 P04141 denotes CSF
T6728 626-635 P42574 denotes caspase-3
T6729 679-684 P09603 denotes M-CSF
T6730 681-684 P04141 denotes CSF
T6731 747-752 P09603 denotes M-CSF
T6732 749-752 P04141 denotes CSF
T6733 2043-2048 P09603 denotes M-CSF
T6734 2045-2048 P04141 denotes CSF
T6735 2134-2143 P08758 denotes Annexin V
T6736 2191-2196 P09603 denotes M-CSF
T6737 2193-2196 P04141 denotes CSF
T6738 2219-2228 P08758 denotes Annexin V
T6739 2277-2282 P09603 denotes M-CSF
T6740 2279-2282 P04141 denotes CSF
T6741 2372-2377 P09603 denotes M-CSF
T6742 2374-2377 P04141 denotes CSF
T23953 1083-1088 P09603 denotes M-CSF
T23954 1085-1088 P04141 denotes CSF
T23955 1277-1286 P42574 denotes caspase-3
T23956 1318-1325 P60709 denotes β-actin
T23957 1380-1389 P42574 denotes caspase-3
T23958 1417-1424 P60709 denotes β-actin
T23959 1606-1615 P08758 denotes Annexin V
T23960 1723-1732 P08758 denotes Annexin V
T23961 1781-1786 P09603 denotes M-CSF
T23962 1783-1786 P04141 denotes CSF
T23963 1917-1922 P09603 denotes M-CSF
T23964 1919-1922 P04141 denotes CSF
T23965 1943-1948 P09603 denotes M-CSF
T23966 1945-1948 P04141 denotes CSF

bionlp-st-ge-2016-reference

Id Subject Object Predicate Lexical cue
T6743 241-251 Positive_regulation denotes expression
T6744 255-262 Protein_catabolism denotes cleaved
T6745 467-474 Protein_catabolism denotes cleaved
T6746 489-497 Positive_regulation denotes elevated
T6747 613-617 Negative_regulation denotes less
T6748 618-625 Protein_catabolism denotes cleaved
T6749 2232-2240 Negative_regulation denotes negative
T6750 263-272 Protein denotes caspase-3
T6751 475-484 Protein denotes caspase-3
T6752 626-635 Protein denotes caspase-3
T6753 2134-2143 Protein denotes Annexin V
T6754 2219-2228 Protein denotes Annexin V
T6755 59-64 Protein denotes M-CSF
T6756 160-165 Protein denotes M-CSF
T6757 340-345 Protein denotes M-CSF
T6758 460-465 Protein denotes M-CSF
T6759 591-596 Protein denotes M-CSF
T6760 679-684 Protein denotes M-CSF
T6761 747-752 Protein denotes M-CSF
T6762 2043-2048 Protein denotes M-CSF
T6763 2191-2196 Protein denotes M-CSF
T6764 2277-2282 Protein denotes M-CSF
T6765 2372-2377 Protein denotes M-CSF
T6766 317-325 Positive_regulation denotes presence
T6767 329-336 Negative_regulation denotes absence
T6768 2197-2204 Negative_regulation denotes reduced
T23967 1373-1379 Positive_regulation denotes active
T23968 1736-1744 Negative_regulation denotes negative
T23969 1318-1325 Protein denotes β-actin
T23970 1380-1389 Protein denotes caspase-3
T23971 1417-1424 Protein denotes β-actin
T23972 1606-1615 Protein denotes Annexin V
T23973 1723-1732 Protein denotes Annexin V
T23974 1083-1088 Protein denotes M-CSF
T23975 1781-1786 Protein denotes M-CSF
T23976 1917-1922 Protein denotes M-CSF
T23977 1943-1948 Protein denotes M-CSF
R5069 T6744 T6743 themeOf cleaved,expression
R5070 T6745 T6746 themeOf cleaved,elevated
R5071 T6748 T6747 themeOf cleaved,less
R5072 T6749 T6768 themeOf negative,reduced
R5073 T6750 T6744 themeOf caspase-3,cleaved
R5074 T6751 T6745 themeOf caspase-3,cleaved
R5075 T6752 T6748 themeOf caspase-3,cleaved
R5076 T6754 T6749 themeOf Annexin V,negative
R5077 T6757 T6767 themeOf M-CSF,absence
R5078 T6757 T6766 themeOf M-CSF,presence
R5079 T6758 T6746 causeOf M-CSF,elevated
R5080 T6759 T6747 causeOf M-CSF,less
R5081 T6763 T6768 causeOf M-CSF,reduced
R18343 T23970 T23967 themeOf caspase-3,active
R18344 T23973 T23968 themeOf Annexin V,negative

bionlp-st-ge-2016-reference-tees

Id Subject Object Predicate Lexical cue
T6943 0-5 Protein denotes NF-κB
T6944 10-13 Protein denotes PKC
T6945 25-34 Protein denotes Human MDM
T6946 59-64 Protein denotes M-CSF
T6947 17-24 Positive_regulation denotes Mediate
T6948 17-24 Positive_regulation denotes Mediate
T6949 65-76 Positive_regulation denotes Stimulation
T6950 83-86 Protein denotes PKC
T6951 91-96 Protein denotes NF-κB
T6952 160-165 Protein denotes M-CSF
T6953 197-200 Protein denotes PKC
T6954 263-272 Protein denotes caspase-3
T6955 340-345 Protein denotes M-CSF
T6956 350-353 Protein denotes PKC
T6957 241-251 Gene_expression denotes expression
T6958 354-364 Negative_regulation denotes inhibitors
T6959 354-364 Negative_regulation denotes inhibitors
T6960 390-393 Protein denotes PKC
T6961 460-465 Protein denotes M-CSF
T6962 475-484 Protein denotes caspase-3
T6963 489-497 Positive_regulation denotes elevated
T6964 591-596 Protein denotes M-CSF
T6965 679-684 Protein denotes M-CSF
T6966 690-693 Protein denotes PKC
T6967 694-704 Negative_regulation denotes inhibitors
T6968 747-752 Protein denotes M-CSF
T6969 761-766 Protein denotes NF-κB
T6970 806-810 Protein denotes PKCs
T6971 822-826 Protein denotes PKCs
T6972 753-760 Positive_regulation denotes induced
T6973 780-789 Regulation denotes regulated
T6974 1979-1982 Protein denotes PKC
T6975 2043-2048 Protein denotes M-CSF
T6976 2079-2082 Protein denotes PKC
T6977 1983-1993 Negative_regulation denotes inhibition
T6978 2083-2093 Negative_regulation denotes inhibitors
T6979 2157-2160 Protein denotes PKC
T6980 2191-2196 Protein denotes M-CSF
T6981 2277-2282 Protein denotes M-CSF
T6982 2161-2171 Negative_regulation denotes inhibitors
T6983 2344-2347 Protein denotes MDM
T6984 2372-2377 Protein denotes M-CSF
T6985 2415-2419 Protein denotes PKCs
T6986 2424-2429 Protein denotes NF-κB
T24061 886-889 Protein denotes PKC
T24062 893-898 Protein denotes NF-κB
T24063 872-882 Negative_regulation denotes Inhibition
T24064 872-882 Negative_regulation denotes Inhibition
T24065 1083-1088 Protein denotes M-CSF
T24066 1277-1286 Protein denotes caspase-3
T24067 1318-1325 Protein denotes β-actin
T24068 1380-1389 Protein denotes caspase-3
T24069 1417-1424 Protein denotes β-actin
T24070 1425-1432 Regulation denotes control
T24071 1917-1922 Protein denotes M-CSF
R5150 T6943 T6947 causeOf NF-κB,Mediate
R5151 T6944 T6948 causeOf PKC,Mediate
R5152 T6945 T6947 themeOf Human MDM,Mediate
R5153 T6945 T6948 themeOf Human MDM,Mediate
R5154 T6946 T6949 themeOf M-CSF,Stimulation
R5155 T6954 T6957 themeOf caspase-3,expression
R5156 T6955 T6958 themeOf M-CSF,inhibitors
R5157 T6956 T6959 themeOf PKC,inhibitors
R5158 T6962 T6963 themeOf caspase-3,elevated
R5159 T6966 T6967 themeOf PKC,inhibitors
R5160 T6968 T6972 causeOf M-CSF,induced
R5161 T6969 T6972 themeOf NF-κB,induced
R5162 T6970 T6973 causeOf PKCs,regulated
R5163 T6972 T6973 themeOf induced,regulated
R5164 T6974 T6977 themeOf PKC,inhibition
R5165 T6976 T6978 themeOf PKC,inhibitors
R5166 T6979 T6982 themeOf PKC,inhibitors
R18355 T24061 T24063 themeOf PKC,Inhibition
R18356 T24062 T24064 themeOf NF-κB,Inhibition
R18357 T24069 T24070 themeOf β-actin,control

events-check-again

Id Subject Object Predicate Lexical cue
T6917 59-64 Protein denotes M-CSF
T6918 160-165 Protein denotes M-CSF
T6919 241-251 Positive_regulation denotes expression
T6920 255-262 Protein_catabolism denotes cleaved
T6921 263-272 Protein denotes caspase-3
T6922 317-325 Positive_regulation denotes presence
T6923 329-336 Negative_regulation denotes absence
T6924 340-345 Protein denotes M-CSF
T6925 460-465 Protein denotes M-CSF
T6926 467-474 Protein_catabolism denotes cleaved
T6927 475-484 Protein denotes caspase-3
T6928 489-497 Positive_regulation denotes elevated
T6929 591-596 Protein denotes M-CSF
T6930 613-617 Negative_regulation denotes less
T6931 618-625 Protein_catabolism denotes cleaved
T6932 626-635 Protein denotes caspase-3
T6933 679-684 Protein denotes M-CSF
T6934 747-752 Protein denotes M-CSF
T6935 2043-2048 Protein denotes M-CSF
T6936 2134-2143 Protein denotes Annexin V
T6937 2191-2196 Protein denotes M-CSF
T6938 2197-2204 Negative_regulation denotes reduced
T6939 2219-2228 Protein denotes Annexin V
T6940 2232-2240 Negative_regulation denotes negative
T6941 2277-2282 Protein denotes M-CSF
T6942 2372-2377 Protein denotes M-CSF
T24050 1083-1088 Protein denotes M-CSF
T24051 1318-1325 Protein denotes β-actin
T24052 1373-1379 Positive_regulation denotes active
T24053 1380-1389 Protein denotes caspase-3
T24054 1417-1424 Protein denotes β-actin
T24055 1606-1615 Protein denotes Annexin V
T24056 1723-1732 Protein denotes Annexin V
T24057 1736-1744 Negative_regulation denotes negative
T24058 1781-1786 Protein denotes M-CSF
T24059 1917-1922 Protein denotes M-CSF
T24060 1943-1948 Protein denotes M-CSF
R5137 T6920 T6919 themeOf cleaved,expression
R5138 T6921 T6920 themeOf caspase-3,cleaved
R5139 T6924 T6923 themeOf M-CSF,absence
R5140 T6924 T6922 themeOf M-CSF,presence
R5141 T6925 T6928 causeOf M-CSF,elevated
R5142 T6926 T6928 themeOf cleaved,elevated
R5143 T6927 T6926 themeOf caspase-3,cleaved
R5144 T6929 T6930 causeOf M-CSF,less
R5145 T6931 T6930 themeOf cleaved,less
R5146 T6932 T6931 themeOf caspase-3,cleaved
R5147 T6937 T6938 causeOf M-CSF,reduced
R5148 T6939 T6940 themeOf Annexin V,negative
R5149 T6940 T6938 themeOf negative,reduced
R18353 T24053 T24052 themeOf caspase-3,active
R18354 T24056 T24057 themeOf Annexin V,negative

GO-CC

Id Subject Object Predicate Lexical cue
T6786 113-117 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T6787 175-179 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T6788 2004-2008 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T6789 2019-2024 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T6790 2258-2263 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T23992 1114-1119 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T23993 1716-1721 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T23994 1754-1759 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T23995 1229-1237 http://purl.obolibrary.org/obo/GO_0019815 denotes antibody
T23996 1229-1237 http://purl.obolibrary.org/obo/GO_0042571 denotes antibody

GO-MF

Id Subject Object Predicate Lexical cue
T6777 10-13 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6778 83-86 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6779 197-200 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6780 350-353 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6781 390-393 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6782 690-693 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6783 1979-1982 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6784 2079-2082 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T6785 2157-2160 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T23990 886-889 http://purl.obolibrary.org/obo/GO_0004697 denotes PKC
T23991 1229-1237 http://purl.obolibrary.org/obo/GO_0003823 denotes antibody

GO-BP

Id Subject Object Predicate Lexical cue
T6987 47-64 http://purl.obolibrary.org/obo/GO_1903969 denotes Response to M-CSF
T6988 47-64 http://purl.obolibrary.org/obo/GO_0036005 denotes Response to M-CSF
T6989 47-64 http://purl.obolibrary.org/obo/GO_1903970 denotes Response to M-CSF
T6990 47-64 http://purl.obolibrary.org/obo/GO_1903971 denotes Response to M-CSF
T6991 226-235 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T6992 286-295 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T6993 2121-2130 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T6994 226-235 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6995 286-295 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6996 2121-2130 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24072 907-916 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T24073 1555-1564 http://purl.obolibrary.org/obo/GO_0006915 denotes Apoptosis
T24074 907-916 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24075 1555-1564 http://purl.obolibrary.org/obo/GO_0097194 denotes Apoptosis

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T6491 0-5 NN denotes NF-κB
T6492 6-9 CC denotes and
T6493 10-13 NN denotes PKC
T6494 13-14 -LRB- denotes (
T6495 14-15 NN denotes s
T6496 15-16 -RRB- denotes )
T6497 17-24 VB denotes Mediate
T6498 25-30 JJ denotes Human
T6499 31-34 NN denotes MDM
T6500 35-43 NN denotes Survival
T6501 44-46 IN denotes in
T6502 47-55 NN denotes Response
T6503 56-58 TO denotes to
T6504 59-64 NN denotes M-CSF
T6505 65-76 NN denotes Stimulation
T6506 77-82 IN denotes Since
T6507 83-86 NN denotes PKC
T6508 87-90 CC denotes and
T6509 91-96 NN denotes NF-κB
T6510 97-100 VB denotes are
T6511 101-109 JJ denotes critical
T6512 110-112 IN denotes in
T6513 113-117 NN denotes cell
T6514 118-126 NN denotes survival
T6515 127-128 -LRB- denotes [
T6516 128-130 CD denotes 37
T6517 130-131 -RRB- denotes ]
T6518 131-132 -COMMA- denotes ,
T6519 133-134 -LRB- denotes [
T6520 134-136 CD denotes 38
T6521 136-137 -RRB- denotes ]
T6522 137-138 -COMMA- denotes ,
T6523 139-141 PRP denotes we
T6524 142-154 VB denotes hypothesized
T6525 155-159 IN denotes that
T6526 160-165 NN denotes M-CSF
T6527 166-174 VB denotes promoted
T6528 175-179 NN denotes cell
T6529 180-188 NN denotes survival
T6530 189-196 IN denotes through
T6531 197-200 NN denotes PKC
T6532 201-203 IN denotes in
T6533 204-209 JJ denotes human
T6534 210-215 NN denotes MDMs.
T6535 216-218 TO denotes To
T6536 219-225 VB denotes detect
T6537 226-235 NN denotes apoptosis
T6538 235-236 -COMMA- denotes ,
T6539 237-240 DT denotes the
T6540 241-251 NN denotes expression
T6541 252-254 IN denotes of
T6542 255-262 VB denotes cleaved
T6543 263-272 NN denotes caspase-3
T6544 272-273 -COMMA- denotes ,
T6545 274-275 DT denotes a
T6546 276-282 NN denotes marker
T6547 283-285 IN denotes of
T6548 286-295 NN denotes apoptosis
T6549 295-296 -COMMA- denotes ,
T6550 297-300 VB denotes was
T6551 301-309 VB denotes analyzed
T6552 310-312 IN denotes in
T6553 313-316 DT denotes the
T6554 317-325 NN denotes presence
T6555 326-328 CC denotes or
T6556 329-336 NN denotes absence
T6557 337-339 IN denotes of
T6558 340-345 NN denotes M-CSF
T6559 346-349 CC denotes and
T6560 350-353 NN denotes PKC
T6561 354-364 NN denotes inhibitors
T6562 366-368 IN denotes In
T6563 369-373 NN denotes MDMs
T6564 374-384 VB denotes pretreated
T6565 385-389 IN denotes with
T6566 390-393 NN denotes PKC
T6567 394-404 NN denotes inhibitors
T6568 405-406 -LRB- denotes (
T6569 406-416 NN denotes Ro-31-8220
T6570 416-417 -COMMA- denotes ,
T6571 418-425 NN denotes Gö-6976
T6572 425-426 -COMMA- denotes ,
T6573 427-429 CC denotes or
T6574 430-438 NN denotes BAPTA/AM
T6575 438-439 -RRB- denotes )
T6576 440-443 CC denotes and
T6577 444-454 VB denotes stimulated
T6578 455-459 IN denotes with
T6579 460-465 NN denotes M-CSF
T6580 465-466 -COMMA- denotes ,
T6581 467-474 VB denotes cleaved
T6582 475-484 NN denotes caspase-3
T6583 485-488 VB denotes was
T6584 489-497 VB denotes elevated
T6585 498-500 TO denotes to
T6586 501-507 NN denotes levels
T6587 508-510 IN denotes of
T6588 511-516 NN denotes cells
T6589 517-524 VB denotes treated
T6590 525-529 IN denotes with
T6591 530-537 NN denotes vehicle
T6592 538-543 RB denotes alone
T6593 544-545 -LRB- denotes (
T6594 545-551 NN denotes Figure
T6595 552-554 NN denotes 3A
T6596 554-555 -RRB- denotes )
T6597 557-559 IN denotes In
T6598 560-568 NN denotes contrast
T6599 568-569 -COMMA- denotes ,
T6600 570-575 NN denotes cells
T6601 576-585 VB denotes incubated
T6602 586-590 IN denotes with
T6603 591-596 NN denotes M-CSF
T6604 597-600 CC denotes and
T6605 601-608 NN denotes vehicle
T6606 609-612 VB denotes had
T6607 613-617 RB denotes less
T6608 618-625 JJ denotes cleaved
T6609 626-635 NN denotes caspase-3
T6610 636-640 IN denotes than
T6611 641-646 NN denotes cells
T6612 647-656 VB denotes incubated
T6613 657-661 IN denotes with
T6614 662-669 NN denotes vehicle
T6615 670-675 RB denotes alone
T6616 676-678 CC denotes or
T6617 679-684 NN denotes M-CSF
T6618 685-689 IN denotes with
T6619 690-693 NN denotes PKC
T6620 694-704 NN denotes inhibitors
T6621 706-711 DT denotes These
T6622 712-716 NN denotes data
T6623 717-726 VB denotes supported
T6624 727-730 DT denotes the
T6625 731-741 NN denotes hypothesis
T6626 742-746 IN denotes that
T6627 747-760 JJ denotes M-CSF-induced
T6628 761-766 NN denotes NF-κB
T6629 767-775 NN denotes activity
T6630 776-779 VB denotes was
T6631 780-789 VB denotes regulated
T6632 790-792 IN denotes by
T6633 793-805 JJ denotes conventional
T6634 806-810 NN denotes PKCs
T6635 810-811 -COMMA- denotes ,
T6636 812-815 RB denotes not
T6637 816-821 JJ denotes novel
T6638 822-826 NN denotes PKCs
T6639 1963-1965 TO denotes To
T6640 1966-1973 VB denotes confirm
T6641 1974-1978 IN denotes that
T6642 1979-1982 NN denotes PKC
T6643 1983-1993 NN denotes inhibition
T6644 1994-2003 VB denotes decreased
T6645 2004-2008 NN denotes cell
T6646 2009-2017 NN denotes survival
T6647 2017-2018 -COMMA- denotes ,
T6648 2019-2024 NN denotes cells
T6649 2025-2029 VB denotes were
T6650 2030-2037 VB denotes treated
T6651 2038-2042 IN denotes with
T6652 2043-2048 NN denotes M-CSF
T6653 2049-2051 IN denotes in
T6654 2052-2055 DT denotes the
T6655 2056-2063 NN denotes absence
T6656 2064-2066 CC denotes or
T6657 2067-2075 NN denotes presence
T6658 2076-2078 IN denotes of
T6659 2079-2082 NN denotes PKC
T6660 2083-2093 NN denotes inhibitors
T6661 2094-2097 CC denotes and
T6662 2098-2102 RB denotes then
T6663 2103-2107 RB denotes also
T6664 2108-2116 VB denotes examined
T6665 2117-2120 IN denotes for
T6666 2121-2130 NN denotes apoptosis
T6667 2131-2133 IN denotes by
T6668 2134-2141 NN denotes Annexin
T6669 2142-2146 NN denotes V/PI
T6670 2147-2155 NN denotes staining
T6671 2157-2160 NN denotes PKC
T6672 2161-2171 NN denotes inhibitors
T6673 2172-2174 IN denotes in
T6674 2175-2178 DT denotes the
T6675 2179-2187 NN denotes presence
T6676 2188-2190 IN denotes of
T6677 2191-2196 NN denotes M-CSF
T6678 2197-2204 VB denotes reduced
T6679 2205-2208 DT denotes the
T6680 2209-2215 NN denotes number
T6681 2216-2218 IN denotes of
T6682 2219-2226 NNP denotes Annexin
T6683 2227-2231 NNP denotes V/PI
T6684 2232-2240 JJ denotes negative
T6685 2241-2245 NN denotes MDMs
T6686 2246-2254 VB denotes compared
T6687 2255-2257 TO denotes to
T6688 2258-2263 NN denotes cells
T6689 2264-2271 VB denotes treated
T6690 2272-2276 IN denotes with
T6691 2277-2282 NN denotes M-CSF
T6692 2283-2288 RB denotes alone
T6693 2289-2290 -LRB- denotes (
T6694 2290-2296 NN denotes Figure
T6695 2297-2299 NN denotes 3B
T6696 2299-2300 -RRB- denotes )
T6697 2302-2307 DT denotes These
T6698 2308-2320 NN denotes observations
T6699 2321-2328 RB denotes further
T6700 2329-2338 VB denotes suggested
T6701 2339-2343 IN denotes that
T6702 2344-2347 NN denotes MDM
T6703 2348-2356 NN denotes survival
T6704 2357-2359 VB denotes is
T6705 2360-2368 VB denotes promoted
T6706 2369-2371 IN denotes by
T6707 2372-2377 NN denotes M-CSF
T6708 2378-2381 CC denotes and
T6709 2382-2392 RB denotes critically
T6710 2393-2401 VB denotes involves
T6711 2402-2414 JJ denotes conventional
T6712 2415-2419 NN denotes PKCs
T6713 2420-2423 CC denotes and
T6714 2424-2429 NN denotes NF-κB
T6715 2430-2438 NN denotes activity
T23763 872-882 NN denotes Inhibition
T23764 883-885 IN denotes of
T23765 886-889 NN denotes PKC
T23766 890-892 CC denotes or
T23767 893-898 NN denotes NF-κB
T23768 899-906 VB denotes induces
T23769 907-916 NN denotes apoptosis
T23770 917-919 IN denotes in
T23771 920-924 NN denotes MDMs
T23772 926-927 -LRB- denotes (
T23773 927-928 NN denotes A
T23774 928-929 -RRB- denotes )
T23775 930-934 NN denotes MDMs
T23776 935-939 VB denotes were
T23777 940-953 JJ denotes pre-incubated
T23778 954-956 IN denotes in
T23779 957-961 NN denotes RPMI
T23780 962-968 NN denotes medium
T23781 969-979 VB denotes containing
T23782 980-990 NN denotes inhibitors
T23783 991-992 -LRB- denotes (
T23784 992-1002 NN denotes Ro-31-8220
T23785 1002-1003 -COLON- denotes :
T23786 1004-1005 CD denotes 5
T23787 1006-1008 NN denotes µM
T23788 1008-1009 -COMMA- denotes ,
T23789 1010-1017 NN denotes Gö-6976
T23790 1017-1018 -COLON- denotes :
T23791 1019-1020 CD denotes 5
T23792 1021-1023 NN denotes µM
T23793 1023-1024 -COMMA- denotes ,
T23794 1025-1033 NNP denotes BAPTA/AM
T23795 1033-1034 -COLON- denotes :
T23796 1035-1038 CD denotes 2.5
T23797 1039-1041 NN denotes µM
T23798 1041-1042 -RRB- denotes )
T23799 1043-1046 IN denotes for
T23800 1047-1049 CD denotes 30
T23801 1050-1057 NN denotes minutes
T23802 1058-1063 RB denotes prior
T23803 1064-1066 TO denotes to
T23804 1067-1070 DT denotes the
T23805 1071-1079 NN denotes addition
T23806 1080-1082 IN denotes of
T23807 1083-1088 NN denotes M-CSF
T23808 1090-1092 IN denotes As
T23809 1093-1094 DT denotes a
T23810 1095-1102 NN denotes control
T23811 1102-1103 -COMMA- denotes ,
T23812 1104-1113 JJ denotes untreated
T23813 1114-1119 NN denotes cells
T23814 1120-1124 VB denotes were
T23815 1125-1134 VB denotes incubated
T23816 1135-1139 IN denotes with
T23817 1140-1148 NN denotes dimethyl
T23818 1149-1158 NN denotes sulfoxide
T23819 1159-1160 -LRB- denotes (
T23820 1160-1164 NN denotes DMSO
T23821 1164-1165 -RRB- denotes )
T23822 1167-1171 NN denotes Cell
T23823 1172-1179 NN denotes lysates
T23824 1180-1184 VB denotes were
T23825 1185-1193 VB denotes resolved
T23826 1194-1196 IN denotes by
T23827 1197-1205 NN denotes SDS-PAGE
T23828 1206-1209 CC denotes and
T23829 1210-1223 VB denotes immunoblotted
T23830 1224-1228 IN denotes with
T23831 1229-1237 NN denotes antibody
T23832 1238-1249 VB denotes recognizing
T23833 1250-1253 DT denotes the
T23834 1254-1260 JJ denotes active
T23835 1261-1268 JJ denotes cleaved
T23836 1269-1273 NN denotes form
T23837 1274-1276 IN denotes of
T23838 1277-1286 NN denotes caspase-3
T23839 1288-1291 DT denotes The
T23840 1292-1297 NN denotes blots
T23841 1298-1302 VB denotes were
T23842 1303-1312 VB denotes reblotted
T23843 1313-1317 IN denotes with
T23844 1318-1325 NN denotes β-actin
T23845 1326-1330 WDT denotes that
T23846 1331-1337 VB denotes served
T23847 1338-1340 IN denotes as
T23848 1341-1342 DT denotes a
T23849 1343-1350 NN denotes loading
T23850 1351-1358 NN denotes control
T23851 1360-1363 DT denotes The
T23852 1364-1369 NN denotes ratio
T23853 1370-1372 IN denotes of
T23854 1373-1379 JJ denotes active
T23855 1380-1389 NN denotes caspase-3
T23856 1390-1395 NN denotes bands
T23857 1396-1397 -LRB- denotes (
T23858 1397-1399 CD denotes 17
T23859 1400-1402 NN denotes kD
T23860 1403-1406 CC denotes and
T23861 1407-1409 CD denotes 19
T23862 1410-1412 NN denotes kD
T23863 1412-1413 -RRB- denotes )
T23864 1414-1416 TO denotes to
T23865 1417-1424 NN denotes β-actin
T23866 1425-1432 NN denotes control
T23867 1433-1436 VB denotes was
T23868 1437-1447 VB denotes determined
T23869 1448-1450 IN denotes by
T23870 1451-1463 NN denotes densitometry
T23871 1464-1472 NN denotes analysis
T23872 1473-1474 -LRB- denotes (
T23873 1474-1480 NN denotes bottom
T23874 1481-1486 NN denotes panel
T23875 1486-1487 -RRB- denotes )
T23876 1489-1493 NN denotes Data
T23877 1494-1504 VB denotes represents
T23878 1505-1508 DT denotes the
T23879 1509-1513 JJ denotes mean
T23880 1514-1515 JJ denotes ±
T23881 1516-1521 NN denotes S.E.M
T23882 1522-1526 IN denotes from
T23883 1527-1530 CD denotes two
T23884 1531-1542 JJ denotes independent
T23885 1543-1550 NN denotes donors.
T23886 1551-1552 -LRB- denotes (
T23887 1552-1553 NN denotes B
T23888 1553-1554 -RRB- denotes )
T23889 1555-1564 NN denotes Apoptosis
T23890 1565-1567 IN denotes of
T23891 1568-1571 DT denotes the
T23892 1572-1579 VB denotes treated
T23893 1580-1584 NN denotes MDMs
T23894 1585-1588 VB denotes was
T23895 1589-1593 RB denotes also
T23896 1594-1602 VB denotes measured
T23897 1603-1605 IN denotes by
T23898 1606-1613 NN denotes Annexin
T23899 1614-1620 NN denotes V-FITC
T23900 1621-1624 CC denotes and
T23901 1625-1634 NN denotes propidium
T23902 1635-1641 NN denotes iodine
T23903 1642-1643 -LRB- denotes (
T23904 1643-1645 NN denotes PI
T23905 1645-1646 -RRB- denotes )
T23906 1647-1655 NN denotes staining
T23907 1656-1659 CC denotes and
T23908 1660-1668 VB denotes analyzed
T23909 1669-1671 IN denotes by
T23910 1672-1676 NN denotes flow
T23911 1677-1686 NN denotes cytometry
T23912 1688-1691 DT denotes The
T23913 1692-1702 NN denotes percentage
T23914 1703-1705 IN denotes of
T23915 1706-1715 VB denotes surviving
T23916 1716-1721 NN denotes cells
T23917 1722-1723 -LRB- denotes (
T23918 1723-1730 NN denotes Annexin
T23919 1731-1735 NN denotes V/PI
T23920 1736-1744 JJ denotes negative
T23921 1744-1745 -RRB- denotes )
T23922 1746-1749 IN denotes for
T23923 1750-1753 DT denotes the
T23924 1754-1759 NN denotes cells
T23925 1760-1767 VB denotes treated
T23926 1768-1772 IN denotes with
T23927 1773-1786 NN denotes vehicle/M-CSF
T23928 1787-1790 VB denotes was
T23929 1791-1802 RB denotes arbitrarily
T23930 1803-1806 VB denotes set
T23931 1807-1809 IN denotes as
T23932 1810-1813 CD denotes 100
T23933 1815-1819 NN denotes Data
T23934 1820-1825 VB denotes shown
T23935 1826-1835 VB denotes represent
T23936 1836-1839 DT denotes the
T23937 1840-1844 JJ denotes mean
T23938 1845-1846 JJ denotes ±
T23939 1847-1852 NN denotes S.E.M
T23940 1853-1857 IN denotes from
T23941 1858-1863 CD denotes three
T23942 1864-1875 JJ denotes independent
T23943 1876-1888 NN denotes experiments.
T23944 1889-1893 NNP denotes *The
T23945 1894-1902 NN denotes p-values
T23946 1903-1905 IN denotes of
T23947 1906-1922 NN denotes inhibitors/M-CSF
T23948 1923-1931 VB denotes compared
T23949 1932-1934 TO denotes to
T23950 1935-1948 NN denotes vehicle/M-CSF
T23951 1949-1953 VB denotes were
T23952 1954-1959 CD denotes ≤0.05
R4840 T6491 T6492 arg1Of NF-κB,and
R4841 T6492 T6497 arg1Of and,Mediate
R4842 T6493 T6492 arg2Of PKC,and
R4843 T6493 T6494 arg1Of PKC,(
R4844 T6495 T6494 arg2Of s,(
R4845 T6496 T6494 arg3Of ),(
R4846 T6497 T6501 arg1Of Mediate,in
R4847 T6500 T6497 arg2Of Survival,Mediate
R4848 T6500 T6498 arg1Of Survival,Human
R4849 T6500 T6499 arg1Of Survival,MDM
R4850 T6502 T6501 arg2Of Response,in
R4851 T6502 T6503 arg1Of Response,to
R4852 T6505 T6503 arg2Of Stimulation,to
R4853 T6505 T6504 arg1Of Stimulation,M-CSF
R4854 T6507 T6508 arg1Of PKC,and
R4855 T6508 T6510 arg1Of and,are
R4856 T6508 T6511 arg1Of and,critical
R4857 T6509 T6508 arg2Of NF-κB,and
R4858 T6510 T6506 arg2Of are,Since
R4859 T6510 T6518 arg1Of are,","
R4860 T6510 T6519 arg1Of are,[
R4861 T6511 T6510 arg2Of critical,are
R4862 T6511 T6512 arg1Of critical,in
R4863 T6514 T6512 arg2Of survival,in
R4864 T6514 T6513 arg1Of survival,cell
R4865 T6514 T6515 arg1Of survival,[
R4866 T6516 T6515 arg2Of 37,[
R4867 T6517 T6515 arg3Of ],[
R4868 T6520 T6519 arg2Of 38,[
R4869 T6521 T6519 arg3Of ],[
R4870 T6523 T6524 arg1Of we,hypothesized
R4871 T6523 T6550 arg1Of we,was
R4872 T6523 T6551 arg2Of we,analyzed
R4873 T6524 T6549 arg1Of hypothesized,","
R4874 T6526 T6527 arg1Of M-CSF,promoted
R4875 T6527 T6524 arg2Of promoted,hypothesized
R4876 T6527 T6525 arg1Of promoted,that
R4877 T6527 T6530 arg1Of promoted,through
R4878 T6527 T6535 modOf promoted,To
R4879 T6529 T6527 arg2Of survival,promoted
R4880 T6529 T6528 arg1Of survival,cell
R4881 T6531 T6530 arg2Of PKC,through
R4882 T6531 T6532 arg1Of PKC,in
R4883 T6534 T6532 arg2Of MDMs.,in
R4884 T6534 T6533 arg1Of MDMs.,human
R4885 T6536 T6535 arg1Of detect,To
R4886 T6537 T6536 arg2Of apoptosis,detect
R4887 T6537 T6538 arg1Of apoptosis,","
R4888 T6537 T6544 arg1Of apoptosis,","
R4889 T6540 T6538 arg2Of expression,","
R4890 T6540 T6539 arg1Of expression,the
R4891 T6540 T6541 arg1Of expression,of
R4892 T6543 T6541 arg2Of caspase-3,of
R4893 T6543 T6542 arg2Of caspase-3,cleaved
R4894 T6546 T6544 arg2Of marker,","
R4895 T6546 T6545 arg1Of marker,a
R4896 T6546 T6547 arg1Of marker,of
R4897 T6548 T6547 arg2Of apoptosis,of
R4898 T6549 T6506 arg1Of ",",Since
R4899 T6549 T6522 arg1Of ",",","
R4900 T6549 T6552 arg1Of ",",in
R4901 T6551 T6549 arg2Of analyzed,","
R4902 T6551 T6550 arg2Of analyzed,was
R4903 T6554 T6555 arg1Of presence,or
R4904 T6555 T6552 arg2Of or,in
R4905 T6555 T6553 arg1Of or,the
R4906 T6555 T6557 arg1Of or,of
R4907 T6556 T6555 arg2Of absence,or
R4908 T6558 T6559 arg1Of M-CSF,and
R4909 T6560 T6559 arg2Of PKC,and
R4910 T6561 T6557 arg2Of inhibitors,of
R4911 T6561 T6558 arg1Of inhibitors,M-CSF
R4912 T6561 T6560 arg1Of inhibitors,PKC
R4913 T6563 T6562 arg2Of MDMs,In
R4914 T6563 T6564 arg2Of MDMs,pretreated
R4915 T6563 T6577 arg2Of MDMs,stimulated
R4916 T6564 T6565 arg1Of pretreated,with
R4917 T6564 T6576 arg1Of pretreated,and
R4918 T6567 T6565 arg2Of inhibitors,with
R4919 T6567 T6566 arg1Of inhibitors,PKC
R4920 T6567 T6568 arg1Of inhibitors,(
R4921 T6569 T6570 arg1Of Ro-31-8220,","
R4922 T6570 T6573 arg1Of ",",or
R4923 T6571 T6570 arg2Of Gö-6976,","
R4924 T6573 T6568 arg2Of or,(
R4925 T6573 T6572 arg1Of or,","
R4926 T6574 T6573 arg2Of BAPTA/AM,or
R4927 T6575 T6568 arg3Of ),(
R4928 T6577 T6576 arg2Of stimulated,and
R4929 T6577 T6578 arg1Of stimulated,with
R4930 T6579 T6578 arg2Of M-CSF,with
R4931 T6582 T6581 arg2Of caspase-3,cleaved
R4932 T6582 T6583 arg1Of caspase-3,was
R4933 T6582 T6584 arg2Of caspase-3,elevated
R4934 T6584 T6562 arg1Of elevated,In
R4935 T6584 T6580 arg1Of elevated,","
R4936 T6584 T6583 arg2Of elevated,was
R4937 T6584 T6585 arg1Of elevated,to
R4938 T6586 T6585 arg2Of levels,to
R4939 T6586 T6587 arg1Of levels,of
R4940 T6588 T6587 arg2Of cells,of
R4941 T6588 T6589 arg2Of cells,treated
R4942 T6589 T6590 arg1Of treated,with
R4943 T6591 T6590 arg2Of vehicle,with
R4944 T6591 T6592 arg1Of vehicle,alone
R4945 T6591 T6593 arg1Of vehicle,(
R4946 T6595 T6593 arg2Of 3A,(
R4947 T6595 T6594 arg1Of 3A,Figure
R4948 T6596 T6593 arg3Of ),(
R4949 T6598 T6597 arg2Of contrast,In
R4950 T6600 T6601 arg2Of cells,incubated
R4951 T6600 T6606 arg1Of cells,had
R4952 T6601 T6602 arg1Of incubated,with
R4953 T6603 T6604 arg1Of M-CSF,and
R4954 T6604 T6602 arg2Of and,with
R4955 T6605 T6604 arg2Of vehicle,and
R4956 T6606 T6597 arg1Of had,In
R4957 T6606 T6599 arg1Of had,","
R4958 T6608 T6607 arg1Of cleaved,less
R4959 T6609 T6606 arg2Of caspase-3,had
R4960 T6609 T6608 arg1Of caspase-3,cleaved
R4961 T6609 T6610 arg1Of caspase-3,than
R4962 T6611 T6610 arg2Of cells,than
R4963 T6611 T6612 arg2Of cells,incubated
R4964 T6612 T6613 arg1Of incubated,with
R4965 T6614 T6615 arg1Of vehicle,alone
R4966 T6614 T6616 arg1Of vehicle,or
R4967 T6616 T6613 arg2Of or,with
R4968 T6617 T6616 arg2Of M-CSF,or
R4969 T6617 T6618 arg1Of M-CSF,with
R4970 T6620 T6618 arg2Of inhibitors,with
R4971 T6620 T6619 arg1Of inhibitors,PKC
R4972 T6622 T6621 arg1Of data,These
R4973 T6622 T6623 arg1Of data,supported
R4974 T6625 T6623 arg2Of hypothesis,supported
R4975 T6625 T6624 arg1Of hypothesis,the
R4976 T6629 T6627 arg1Of activity,M-CSF-induced
R4977 T6629 T6628 arg1Of activity,NF-κB
R4978 T6629 T6630 arg1Of activity,was
R4979 T6629 T6631 arg2Of activity,regulated
R4980 T6631 T6625 arg2Of regulated,hypothesis
R4981 T6631 T6626 arg1Of regulated,that
R4982 T6631 T6630 arg2Of regulated,was
R4983 T6634 T6631 arg1Of PKCs,regulated
R4984 T6634 T6632 arg2Of PKCs,by
R4985 T6634 T6633 arg1Of PKCs,conventional
R4986 T6634 T6635 arg1Of PKCs,","
R4987 T6638 T6635 arg2Of PKCs,","
R4988 T6638 T6636 arg1Of PKCs,not
R4989 T6638 T6637 arg1Of PKCs,novel
R4990 T6640 T6639 arg1Of confirm,To
R4991 T6643 T6642 arg1Of inhibition,PKC
R4992 T6643 T6644 arg1Of inhibition,decreased
R4993 T6644 T6640 arg2Of decreased,confirm
R4994 T6644 T6641 arg1Of decreased,that
R4995 T6646 T6644 arg2Of survival,decreased
R4996 T6646 T6645 arg1Of survival,cell
R4997 T6648 T6640 arg1Of cells,confirm
R4998 T6648 T6649 arg1Of cells,were
R4999 T6648 T6650 arg2Of cells,treated
R5000 T6648 T6664 arg2Of cells,examined
R5001 T6650 T6651 arg1Of treated,with
R5002 T6650 T6653 arg1Of treated,in
R5003 T6650 T6661 arg1Of treated,and
R5004 T6652 T6651 arg2Of M-CSF,with
R5005 T6655 T6656 arg1Of absence,or
R5006 T6656 T6653 arg2Of or,in
R5007 T6656 T6654 arg1Of or,the
R5008 T6656 T6658 arg1Of or,of
R5009 T6657 T6656 arg2Of presence,or
R5010 T6660 T6658 arg2Of inhibitors,of
R5011 T6660 T6659 arg1Of inhibitors,PKC
R5012 T6661 T6639 modOf and,To
R5013 T6661 T6647 arg1Of and,","
R5014 T6661 T6649 arg2Of and,were
R5015 T6664 T6661 arg2Of examined,and
R5016 T6664 T6662 arg1Of examined,then
R5017 T6664 T6663 arg1Of examined,also
R5018 T6664 T6665 arg1Of examined,for
R5019 T6666 T6665 arg2Of apoptosis,for
R5020 T6670 T6664 arg1Of staining,examined
R5021 T6670 T6667 arg2Of staining,by
R5022 T6670 T6668 arg1Of staining,Annexin
R5023 T6670 T6669 arg1Of staining,V/PI
R5024 T6672 T6671 arg1Of inhibitors,PKC
R5025 T6672 T6673 arg1Of inhibitors,in
R5026 T6672 T6678 arg1Of inhibitors,reduced
R5027 T6675 T6673 arg2Of presence,in
R5028 T6675 T6674 arg1Of presence,the
R5029 T6675 T6676 arg1Of presence,of
R5030 T6677 T6676 arg2Of M-CSF,of
R5031 T6678 T6686 arg1Of reduced,compared
R5032 T6680 T6678 arg2Of number,reduced
R5033 T6680 T6679 arg1Of number,the
R5034 T6680 T6681 arg1Of number,of
R5035 T6683 T6682 arg1Of V/PI,Annexin
R5036 T6685 T6681 arg2Of MDMs,of
R5037 T6685 T6683 arg1Of MDMs,V/PI
R5038 T6685 T6684 arg1Of MDMs,negative
R5039 T6687 T6686 arg2Of to,compared
R5040 T6688 T6687 arg2Of cells,to
R5041 T6688 T6689 arg2Of cells,treated
R5042 T6689 T6690 arg1Of treated,with
R5043 T6691 T6690 arg2Of M-CSF,with
R5044 T6691 T6692 arg1Of M-CSF,alone
R5045 T6691 T6693 arg1Of M-CSF,(
R5046 T6695 T6693 arg2Of 3B,(
R5047 T6695 T6694 arg1Of 3B,Figure
R5048 T6696 T6693 arg3Of ),(
R5049 T6698 T6697 arg1Of observations,These
R5050 T6698 T6700 arg1Of observations,suggested
R5051 T6700 T6699 arg1Of suggested,further
R5052 T6703 T6702 arg1Of survival,MDM
R5053 T6703 T6704 arg1Of survival,is
R5054 T6703 T6705 arg2Of survival,promoted
R5055 T6703 T6710 arg1Of survival,involves
R5056 T6705 T6704 arg2Of promoted,is
R5057 T6705 T6708 arg1Of promoted,and
R5058 T6707 T6705 arg1Of M-CSF,promoted
R5059 T6707 T6706 arg2Of M-CSF,by
R5060 T6708 T6700 arg2Of and,suggested
R5061 T6708 T6701 arg1Of and,that
R5062 T6710 T6708 arg2Of involves,and
R5063 T6710 T6709 arg1Of involves,critically
R5064 T6712 T6711 arg1Of PKCs,conventional
R5065 T6712 T6713 arg1Of PKCs,and
R5066 T6713 T6710 arg2Of and,involves
R5067 T6715 T6713 arg2Of activity,and
R5068 T6715 T6714 arg1Of activity,NF-κB
R18154 T23763 T23764 arg1Of Inhibition,of
R18155 T23763 T23768 arg1Of Inhibition,induces
R18156 T23765 T23766 arg1Of PKC,or
R18157 T23766 T23764 arg2Of or,of
R18158 T23767 T23766 arg2Of NF-κB,or
R18159 T23768 T23770 arg1Of induces,in
R18160 T23769 T23768 arg2Of apoptosis,induces
R18161 T23771 T23770 arg2Of MDMs,in
R18162 T23773 T23772 arg2Of A,(
R18163 T23774 T23772 arg3Of ),(
R18164 T23775 T23772 arg1Of MDMs,(
R18165 T23775 T23776 arg1Of MDMs,were
R18166 T23775 T23777 arg1Of MDMs,pre-incubated
R18167 T23776 T23778 arg1Of were,in
R18168 T23777 T23776 arg2Of pre-incubated,were
R18169 T23780 T23778 arg2Of medium,in
R18170 T23780 T23779 arg1Of medium,RPMI
R18171 T23780 T23781 arg1Of medium,containing
R18172 T23782 T23781 arg2Of inhibitors,containing
R18173 T23782 T23783 arg1Of inhibitors,(
R18174 T23784 T23783 arg2Of Ro-31-8220,(
R18175 T23785 T23783 arg3Of :,(
R18176 T23787 T23786 arg1Of µM,5
R18177 T23787 T23788 arg1Of µM,","
R18178 T23789 T23788 arg2Of Gö-6976,","
R18179 T23789 T23790 arg1Of Gö-6976,:
R18180 T23792 T23791 arg1Of µM,5
R18181 T23792 T23793 arg1Of µM,","
R18182 T23794 T23793 arg2Of BAPTA/AM,","
R18183 T23794 T23795 arg1Of BAPTA/AM,:
R18184 T23797 T23796 arg1Of µM,2.5
R18185 T23797 T23798 arg1Of µM,)
R18186 T23797 T23799 arg1Of µM,for
R18187 T23801 T23799 arg2Of minutes,for
R18188 T23801 T23800 arg1Of minutes,30
R18189 T23801 T23803 arg1Of minutes,to
R18190 T23803 T23802 arg1Of to,prior
R18191 T23805 T23803 arg2Of addition,to
R18192 T23805 T23804 arg1Of addition,the
R18193 T23805 T23806 arg1Of addition,of
R18194 T23807 T23806 arg2Of M-CSF,of
R18195 T23810 T23808 arg2Of control,As
R18196 T23810 T23809 arg1Of control,a
R18197 T23813 T23812 arg1Of cells,untreated
R18198 T23813 T23814 arg1Of cells,were
R18199 T23813 T23815 arg2Of cells,incubated
R18200 T23815 T23808 arg1Of incubated,As
R18201 T23815 T23811 arg1Of incubated,","
R18202 T23815 T23814 arg2Of incubated,were
R18203 T23815 T23816 arg1Of incubated,with
R18204 T23818 T23816 arg2Of sulfoxide,with
R18205 T23818 T23817 arg1Of sulfoxide,dimethyl
R18206 T23818 T23819 arg1Of sulfoxide,(
R18207 T23820 T23819 arg2Of DMSO,(
R18208 T23821 T23819 arg3Of ),(
R18209 T23823 T23822 arg1Of lysates,Cell
R18210 T23823 T23824 arg1Of lysates,were
R18211 T23823 T23825 arg2Of lysates,resolved
R18212 T23823 T23829 arg2Of lysates,immunoblotted
R18213 T23825 T23826 arg1Of resolved,by
R18214 T23825 T23828 arg1Of resolved,and
R18215 T23827 T23826 arg2Of SDS-PAGE,by
R18216 T23828 T23824 arg2Of and,were
R18217 T23829 T23828 arg2Of immunoblotted,and
R18218 T23829 T23830 arg1Of immunoblotted,with
R18219 T23831 T23830 arg2Of antibody,with
R18220 T23831 T23832 arg1Of antibody,recognizing
R18221 T23832 T23830 arg3Of recognizing,with
R18222 T23836 T23832 arg2Of form,recognizing
R18223 T23836 T23833 arg1Of form,the
R18224 T23836 T23834 arg1Of form,active
R18225 T23836 T23835 arg1Of form,cleaved
R18226 T23836 T23837 arg1Of form,of
R18227 T23838 T23837 arg2Of caspase-3,of
R18228 T23840 T23839 arg1Of blots,The
R18229 T23840 T23841 arg1Of blots,were
R18230 T23840 T23842 arg2Of blots,reblotted
R18231 T23842 T23841 arg2Of reblotted,were
R18232 T23842 T23843 arg1Of reblotted,with
R18233 T23844 T23843 arg2Of β-actin,with
R18234 T23844 T23845 arg1Of β-actin,that
R18235 T23844 T23846 arg1Of β-actin,served
R18236 T23846 T23847 arg1Of served,as
R18237 T23850 T23847 arg2Of control,as
R18238 T23850 T23848 arg1Of control,a
R18239 T23850 T23849 arg1Of control,loading
R18240 T23852 T23851 arg1Of ratio,The
R18241 T23852 T23853 arg1Of ratio,of
R18242 T23852 T23864 arg1Of ratio,to
R18243 T23852 T23867 arg1Of ratio,was
R18244 T23852 T23868 arg2Of ratio,determined
R18245 T23856 T23853 arg2Of bands,of
R18246 T23856 T23854 arg1Of bands,active
R18247 T23856 T23855 arg1Of bands,caspase-3
R18248 T23856 T23857 arg1Of bands,(
R18249 T23859 T23858 arg1Of kD,17
R18250 T23859 T23860 arg1Of kD,and
R18251 T23860 T23857 arg2Of and,(
R18252 T23862 T23860 arg2Of kD,and
R18253 T23862 T23861 arg1Of kD,19
R18254 T23863 T23857 arg3Of ),(
R18255 T23866 T23864 arg2Of control,to
R18256 T23866 T23865 arg1Of control,β-actin
R18257 T23868 T23867 arg2Of determined,was
R18258 T23871 T23868 arg1Of analysis,determined
R18259 T23871 T23869 arg2Of analysis,by
R18260 T23871 T23870 arg1Of analysis,densitometry
R18261 T23871 T23872 arg1Of analysis,(
R18262 T23874 T23872 arg2Of panel,(
R18263 T23874 T23873 arg1Of panel,bottom
R18264 T23875 T23872 arg3Of ),(
R18265 T23876 T23877 arg1Of Data,represents
R18266 T23881 T23877 arg2Of S.E.M,represents
R18267 T23881 T23878 arg1Of S.E.M,the
R18268 T23881 T23879 arg1Of S.E.M,mean
R18269 T23881 T23880 arg1Of S.E.M,±
R18270 T23881 T23882 arg1Of S.E.M,from
R18271 T23881 T23894 modOf S.E.M,was
R18272 T23885 T23882 arg2Of donors.,from
R18273 T23885 T23883 arg1Of donors.,two
R18274 T23885 T23884 arg1Of donors.,independent
R18275 T23885 T23886 arg1Of donors.,(
R18276 T23887 T23886 arg2Of B,(
R18277 T23888 T23886 arg3Of ),(
R18278 T23889 T23890 arg1Of Apoptosis,of
R18279 T23889 T23894 arg1Of Apoptosis,was
R18280 T23889 T23896 arg2Of Apoptosis,measured
R18281 T23889 T23908 arg2Of Apoptosis,analyzed
R18282 T23893 T23890 arg2Of MDMs,of
R18283 T23893 T23891 arg1Of MDMs,the
R18284 T23893 T23892 arg2Of MDMs,treated
R18285 T23896 T23907 arg1Of measured,and
R18286 T23899 T23898 arg1Of V-FITC,Annexin
R18287 T23899 T23900 arg1Of V-FITC,and
R18288 T23900 T23896 arg1Of and,measured
R18289 T23900 T23897 arg2Of and,by
R18290 T23902 T23901 arg1Of iodine,propidium
R18291 T23902 T23903 arg1Of iodine,(
R18292 T23904 T23903 arg2Of PI,(
R18293 T23905 T23903 arg3Of ),(
R18294 T23906 T23900 arg2Of staining,and
R18295 T23906 T23902 arg1Of staining,iodine
R18296 T23907 T23894 arg2Of and,was
R18297 T23907 T23895 arg1Of and,also
R18298 T23908 T23907 arg2Of analyzed,and
R18299 T23911 T23908 arg1Of cytometry,analyzed
R18300 T23911 T23909 arg2Of cytometry,by
R18301 T23911 T23910 arg1Of cytometry,flow
R18302 T23913 T23912 arg1Of percentage,The
R18303 T23913 T23914 arg1Of percentage,of
R18304 T23913 T23922 arg1Of percentage,for
R18305 T23913 T23928 arg1Of percentage,was
R18306 T23913 T23930 arg2Of percentage,set
R18307 T23916 T23914 arg2Of cells,of
R18308 T23916 T23915 arg1Of cells,surviving
R18309 T23916 T23917 arg1Of cells,(
R18310 T23919 T23917 arg2Of V/PI,(
R18311 T23919 T23918 arg1Of V/PI,Annexin
R18312 T23919 T23920 arg1Of V/PI,negative
R18313 T23921 T23917 arg3Of ),(
R18314 T23924 T23922 arg2Of cells,for
R18315 T23924 T23923 arg1Of cells,the
R18316 T23924 T23925 arg2Of cells,treated
R18317 T23925 T23926 arg1Of treated,with
R18318 T23927 T23926 arg2Of vehicle/M-CSF,with
R18319 T23930 T23928 arg2Of set,was
R18320 T23930 T23929 arg1Of set,arbitrarily
R18321 T23930 T23931 arg1Of set,as
R18322 T23932 T23931 arg2Of 100,as
R18323 T23933 T23934 arg2Of Data,shown
R18324 T23933 T23935 arg1Of Data,represent
R18325 T23939 T23935 arg2Of S.E.M,represent
R18326 T23939 T23936 arg1Of S.E.M,the
R18327 T23939 T23937 arg1Of S.E.M,mean
R18328 T23939 T23938 arg1Of S.E.M,±
R18329 T23939 T23940 arg1Of S.E.M,from
R18330 T23943 T23940 arg2Of experiments.,from
R18331 T23943 T23941 arg1Of experiments.,three
R18332 T23943 T23942 arg1Of experiments.,independent
R18333 T23943 T23951 modOf experiments.,were
R18334 T23945 T23944 arg1Of p-values,*The
R18335 T23945 T23946 arg1Of p-values,of
R18336 T23945 T23951 arg1Of p-values,were
R18337 T23945 T23952 arg1Of p-values,≤0.05
R18338 T23947 T23946 arg2Of inhibitors/M-CSF,of
R18339 T23947 T23948 arg1Of inhibitors/M-CSF,compared
R18340 T23949 T23948 arg2Of to,compared
R18341 T23950 T23949 arg2Of vehicle/M-CSF,to
R18342 T23952 T23951 arg2Of ≤0.05,were

sentences

Id Subject Object Predicate Lexical cue
T6250 0-76 Sentence denotes NF-κB and PKC(s) Mediate Human MDM Survival in Response to M-CSF Stimulation
T6251 77-365 Sentence denotes Since PKC and NF-κB are critical in cell survival [37], [38], we hypothesized that M-CSF promoted cell survival through PKC in human MDMs. To detect apoptosis, the expression of cleaved caspase-3, a marker of apoptosis, was analyzed in the presence or absence of M-CSF and PKC inhibitors.
T6252 366-556 Sentence denotes In MDMs pretreated with PKC inhibitors (Ro-31-8220, Gö-6976, or BAPTA/AM) and stimulated with M-CSF, cleaved caspase-3 was elevated to levels of cells treated with vehicle alone (Figure 3A).
T6253 557-705 Sentence denotes In contrast, cells incubated with M-CSF and vehicle had less cleaved caspase-3 than cells incubated with vehicle alone or M-CSF with PKC inhibitors.
T6254 706-827 Sentence denotes These data supported the hypothesis that M-CSF-induced NF-κB activity was regulated by conventional PKCs, not novel PKCs.
T6255 1963-2156 Sentence denotes To confirm that PKC inhibition decreased cell survival, cells were treated with M-CSF in the absence or presence of PKC inhibitors and then also examined for apoptosis by Annexin V/PI staining.
T6256 2157-2301 Sentence denotes PKC inhibitors in the presence of M-CSF reduced the number of Annexin V/PI negative MDMs compared to cells treated with M-CSF alone (Figure 3B).
T6257 2302-2439 Sentence denotes These observations further suggested that MDM survival is promoted by M-CSF and critically involves conventional PKCs and NF-κB activity.
T23548 872-925 Sentence denotes Inhibition of PKC or NF-κB induces apoptosis in MDMs.
T23549 926-1003 Sentence denotes (A) MDMs were pre-incubated in RPMI medium containing inhibitors (Ro-31-8220:
T23550 1004-1018 Sentence denotes 5 µM, Gö-6976:
T23551 1019-1034 Sentence denotes 5 µM, BAPTA/AM:
T23552 1035-1089 Sentence denotes 2.5 µM) for 30 minutes prior to the addition of M-CSF.
T23553 1090-1166 Sentence denotes As a control, untreated cells were incubated with dimethyl sulfoxide (DMSO).
T23554 1167-1287 Sentence denotes Cell lysates were resolved by SDS-PAGE and immunoblotted with antibody recognizing the active cleaved form of caspase-3.
T23555 1288-1359 Sentence denotes The blots were reblotted with β-actin that served as a loading control.
T23556 1360-1488 Sentence denotes The ratio of active caspase-3 bands (17 kD and 19 kD) to β-actin control was determined by densitometry analysis (bottom panel).
T23557 1489-1687 Sentence denotes Data represents the mean ± S.E.M from two independent donors. (B) Apoptosis of the treated MDMs was also measured by Annexin V-FITC and propidium iodine (PI) staining and analyzed by flow cytometry.
T23558 1688-1814 Sentence denotes The percentage of surviving cells (Annexin V/PI negative) for the cells treated with vehicle/M-CSF was arbitrarily set as 100.
T23559 1815-1960 Sentence denotes Data shown represent the mean ± S.E.M from three independent experiments. *The p-values of inhibitors/M-CSF compared to vehicle/M-CSF were ≤0.05.
T96 0-76 Sentence denotes NF-κB and PKC(s) Mediate Human MDM Survival in Response to M-CSF Stimulation
T97 77-365 Sentence denotes Since PKC and NF-κB are critical in cell survival [37], [38], we hypothesized that M-CSF promoted cell survival through PKC in human MDMs. To detect apoptosis, the expression of cleaved caspase-3, a marker of apoptosis, was analyzed in the presence or absence of M-CSF and PKC inhibitors.
T98 366-556 Sentence denotes In MDMs pretreated with PKC inhibitors (Ro-31-8220, Gö-6976, or BAPTA/AM) and stimulated with M-CSF, cleaved caspase-3 was elevated to levels of cells treated with vehicle alone (Figure 3A).
T99 557-705 Sentence denotes In contrast, cells incubated with M-CSF and vehicle had less cleaved caspase-3 than cells incubated with vehicle alone or M-CSF with PKC inhibitors.
T100 706-827 Sentence denotes These data supported the hypothesis that M-CSF-induced NF-κB activity was regulated by conventional PKCs, not novel PKCs.
T101 828-925 Sentence denotes 10.1371/journal.pone.0028081.g003 Figure 3 Inhibition of PKC or NF-κB induces apoptosis in MDMs.
T102 926-1003 Sentence denotes (A) MDMs were pre-incubated in RPMI medium containing inhibitors (Ro-31-8220:
T103 1004-1018 Sentence denotes 5 µM, Gö-6976:
T104 1019-1034 Sentence denotes 5 µM, BAPTA/AM:
T105 1035-1089 Sentence denotes 2.5 µM) for 30 minutes prior to the addition of M-CSF.
T106 1090-1166 Sentence denotes As a control, untreated cells were incubated with dimethyl sulfoxide (DMSO).
T107 1167-1287 Sentence denotes Cell lysates were resolved by SDS-PAGE and immunoblotted with antibody recognizing the active cleaved form of caspase-3.
T108 1288-1359 Sentence denotes The blots were reblotted with β-actin that served as a loading control.
T109 1360-1488 Sentence denotes The ratio of active caspase-3 bands (17 kD and 19 kD) to β-actin control was determined by densitometry analysis (bottom panel).
T110 1489-1687 Sentence denotes Data represents the mean ± S.E.M from two independent donors. (B) Apoptosis of the treated MDMs was also measured by Annexin V-FITC and propidium iodine (PI) staining and analyzed by flow cytometry.
T111 1688-1814 Sentence denotes The percentage of surviving cells (Annexin V/PI negative) for the cells treated with vehicle/M-CSF was arbitrarily set as 100.
T112 1815-1960 Sentence denotes Data shown represent the mean ± S.E.M from three independent experiments. *The p-values of inhibitors/M-CSF compared to vehicle/M-CSF were ≤0.05.
T113 1963-2156 Sentence denotes To confirm that PKC inhibition decreased cell survival, cells were treated with M-CSF in the absence or presence of PKC inhibitors and then also examined for apoptosis by Annexin V/PI staining.
T114 2157-2301 Sentence denotes PKC inhibitors in the presence of M-CSF reduced the number of Annexin V/PI negative MDMs compared to cells treated with M-CSF alone (Figure 3B).
T115 2302-2439 Sentence denotes These observations further suggested that MDM survival is promoted by M-CSF and critically involves conventional PKCs and NF-κB activity.

2_test

Id Subject Object Predicate Lexical cue
22216091-12861375-90609711 128-130 12861375 denotes 37
22216091-16248967-90609712 134-136 16248967 denotes 38

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T6258 0-5 NN denotes NF-κB
T6259 6-9 CC denotes and
T6260 10-13 NNP denotes PKC
T6261 13-14 -LRB- denotes (
T6262 14-15 PRP denotes s
T6263 15-16 -RRB- denotes )
T6264 17-24 NNP denotes Mediate
T6265 25-30 NNP denotes Human
T6266 31-34 NNP denotes MDM
T6267 35-43 NNP denotes Survival
T6268 44-46 IN denotes in
T6269 47-55 NNP denotes Response
T6270 56-58 TO denotes to
T6271 59-64 NNP denotes M-CSF
T6272 65-76 NNP denotes Stimulation
T6273 77-82 IN denotes Since
T6274 83-86 NNP denotes PKC
T6275 87-90 CC denotes and
T6276 91-96 NNP denotes NF-κB
T6277 97-100 VBP denotes are
T6278 101-109 JJ denotes critical
T6279 110-112 IN denotes in
T6280 113-117 NN denotes cell
T6281 118-126 NN denotes survival
T6282 127-128 NNP denotes [
T6283 128-130 CD denotes 37
T6284 130-131 NNP denotes ]
T6285 131-132 , denotes ,
T6286 133-134 NNP denotes [
T6287 134-136 CD denotes 38
T6288 136-137 NNP denotes ]
T6289 137-138 , denotes ,
T6290 139-141 PRP denotes we
T6291 142-154 VBD denotes hypothesized
T6292 155-159 IN denotes that
T6293 160-165 NNP denotes M-CSF
T6294 166-174 VBD denotes promoted
T6295 175-179 NN denotes cell
T6296 180-188 NN denotes survival
T6297 189-196 IN denotes through
T6298 197-200 NNP denotes PKC
T6299 201-203 IN denotes in
T6300 204-209 JJ denotes human
T6301 210-214 NNS denotes MDMs
T6302 214-215 . denotes .
T6303 216-218 TO denotes To
T6304 219-225 VB denotes detect
T6305 226-235 NN denotes apoptosis
T6306 235-236 , denotes ,
T6307 237-240 DT denotes the
T6308 241-251 NN denotes expression
T6309 252-254 IN denotes of
T6310 255-262 JJ denotes cleaved
T6311 263-272 JJ denotes caspase-3
T6312 272-273 , denotes ,
T6313 274-275 DT denotes a
T6314 276-282 NN denotes marker
T6315 283-285 IN denotes of
T6316 286-295 NN denotes apoptosis
T6317 295-296 , denotes ,
T6318 297-300 VBD denotes was
T6319 301-309 VBN denotes analyzed
T6320 310-312 IN denotes in
T6321 313-316 DT denotes the
T6322 317-325 NN denotes presence
T6323 326-328 CC denotes or
T6324 329-336 NN denotes absence
T6325 337-339 IN denotes of
T6326 340-345 NNP denotes M-CSF
T6327 346-349 CC denotes and
T6328 350-353 NNP denotes PKC
T6329 354-364 NNS denotes inhibitors
T6330 364-365 . denotes .
T6331 366-368 IN denotes In
T6332 369-373 NNS denotes MDMs
T6333 374-384 VBN denotes pretreated
T6334 385-389 IN denotes with
T6335 390-393 NNP denotes PKC
T6336 394-404 NNS denotes inhibitors
T6337 405-406 -LRB- denotes (
T6338 406-416 NN denotes Ro-31-8220
T6339 416-417 , denotes ,
T6340 418-425 NNP denotes Gö-6976
T6341 425-426 , denotes ,
T6342 427-429 CC denotes or
T6343 430-438 NNP denotes BAPTA/AM
T6344 438-439 -RRB- denotes )
T6345 440-443 CC denotes and
T6346 444-454 VBN denotes stimulated
T6347 455-459 IN denotes with
T6348 460-465 NNP denotes M-CSF
T6349 465-466 , denotes ,
T6350 467-474 VBD denotes cleaved
T6351 475-484 JJ denotes caspase-3
T6352 485-488 VBD denotes was
T6353 489-497 VBN denotes elevated
T6354 498-500 TO denotes to
T6355 501-507 NNS denotes levels
T6356 508-510 IN denotes of
T6357 511-516 NNS denotes cells
T6358 517-524 VBN denotes treated
T6359 525-529 IN denotes with
T6360 530-537 NN denotes vehicle
T6361 538-543 RB denotes alone
T6362 544-545 -LRB- denotes (
T6363 545-551 NN denotes Figure
T6364 552-554 NN denotes 3A
T6365 554-555 -RRB- denotes )
T6366 555-556 . denotes .
T6367 557-559 IN denotes In
T6368 560-568 NN denotes contrast
T6369 568-569 , denotes ,
T6370 570-575 NNS denotes cells
T6371 576-585 VBN denotes incubated
T6372 586-590 IN denotes with
T6373 591-596 NNP denotes M-CSF
T6374 597-600 CC denotes and
T6375 601-608 NN denotes vehicle
T6376 609-612 VBD denotes had
T6377 613-617 RBR denotes less
T6378 618-625 JJ denotes cleaved
T6379 626-635 JJ denotes caspase-3
T6380 636-640 IN denotes than
T6381 641-646 NNS denotes cells
T6382 647-656 VBN denotes incubated
T6383 657-661 IN denotes with
T6384 662-669 NN denotes vehicle
T6385 670-675 RB denotes alone
T6386 676-678 CC denotes or
T6387 679-684 RB denotes M-CSF
T6388 685-689 IN denotes with
T6389 690-693 NNP denotes PKC
T6390 694-704 NNS denotes inhibitors
T6391 704-705 . denotes .
T6392 706-711 DT denotes These
T6393 712-716 NNS denotes data
T6394 717-726 VBD denotes supported
T6395 727-730 DT denotes the
T6396 731-741 NN denotes hypothesis
T6397 742-746 WDT denotes that
T6398 747-760 VBD denotes M-CSF-induced
T6399 761-766 JJ denotes NF-κB
T6400 767-775 NN denotes activity
T6401 776-779 VBD denotes was
T6402 780-789 VBN denotes regulated
T6403 790-792 IN denotes by
T6404 793-805 JJ denotes conventional
T6405 806-810 NNS denotes PKCs
T6406 810-811 , denotes ,
T6407 812-815 RB denotes not
T6408 816-821 JJ denotes novel
T6409 822-826 NNS denotes PKCs
T6410 826-827 . denotes .
T6411 1963-1965 TO denotes To
T6412 1966-1973 VB denotes confirm
T6413 1974-1978 DT denotes that
T6414 1979-1982 NNP denotes PKC
T6415 1983-1993 NN denotes inhibition
T6416 1994-2003 VBD denotes decreased
T6417 2004-2008 NN denotes cell
T6418 2009-2017 NN denotes survival
T6419 2017-2018 , denotes ,
T6420 2019-2024 NNS denotes cells
T6421 2025-2029 VBD denotes were
T6422 2030-2037 VBN denotes treated
T6423 2038-2042 IN denotes with
T6424 2043-2048 NNP denotes M-CSF
T6425 2049-2051 IN denotes in
T6426 2052-2055 DT denotes the
T6427 2056-2063 NN denotes absence
T6428 2064-2066 CC denotes or
T6429 2067-2075 NN denotes presence
T6430 2076-2078 IN denotes of
T6431 2079-2082 NNP denotes PKC
T6432 2083-2093 NNS denotes inhibitors
T6433 2094-2097 CC denotes and
T6434 2098-2102 RB denotes then
T6435 2103-2107 RB denotes also
T6436 2108-2116 VBD denotes examined
T6437 2117-2120 IN denotes for
T6438 2121-2130 NN denotes apoptosis
T6439 2131-2133 IN denotes by
T6440 2134-2141 NNP denotes Annexin
T6441 2142-2146 NNP denotes V/PI
T6442 2147-2155 VBG denotes staining
T6443 2155-2156 . denotes .
T6444 2157-2160 NNP denotes PKC
T6445 2161-2171 NNS denotes inhibitors
T6446 2172-2174 IN denotes in
T6447 2175-2178 DT denotes the
T6448 2179-2187 NN denotes presence
T6449 2188-2190 IN denotes of
T6450 2191-2196 NNP denotes M-CSF
T6451 2197-2204 VBD denotes reduced
T6452 2205-2208 DT denotes the
T6453 2209-2215 NN denotes number
T6454 2216-2218 IN denotes of
T6455 2219-2226 NNP denotes Annexin
T6456 2227-2231 NNP denotes V/PI
T6457 2232-2240 JJ denotes negative
T6458 2241-2245 NNS denotes MDMs
T6459 2246-2254 VBN denotes compared
T6460 2255-2257 TO denotes to
T6461 2258-2263 NNS denotes cells
T6462 2264-2271 VBN denotes treated
T6463 2272-2276 IN denotes with
T6464 2277-2282 NNP denotes M-CSF
T6465 2283-2288 RB denotes alone
T6466 2289-2290 -LRB- denotes (
T6467 2290-2296 NN denotes Figure
T6468 2297-2299 NN denotes 3B
T6469 2299-2300 -RRB- denotes )
T6470 2300-2301 . denotes .
T6471 2302-2307 DT denotes These
T6472 2308-2320 NNS denotes observations
T6473 2321-2328 RBR denotes further
T6474 2329-2338 VBD denotes suggested
T6475 2339-2343 IN denotes that
T6476 2344-2347 NNP denotes MDM
T6477 2348-2356 NN denotes survival
T6478 2357-2359 VBZ denotes is
T6479 2360-2368 VBN denotes promoted
T6480 2369-2371 IN denotes by
T6481 2372-2377 NNP denotes M-CSF
T6482 2378-2381 CC denotes and
T6483 2382-2392 RB denotes critically
T6484 2393-2401 VBZ denotes involves
T6485 2402-2414 JJ denotes conventional
T6486 2415-2419 NNS denotes PKCs
T6487 2420-2423 CC denotes and
T6488 2424-2429 JJ denotes NF-κB
T6489 2430-2438 NN denotes activity
T6490 2438-2439 . denotes .
T23560 872-882 NNP denotes Inhibition
T23561 883-885 IN denotes of
T23562 886-889 NNP denotes PKC
T23563 890-892 CC denotes or
T23564 893-898 NNP denotes NF-κB
T23565 899-906 VBZ denotes induces
T23566 907-916 NN denotes apoptosis
T23567 917-919 IN denotes in
T23568 920-924 NNS denotes MDMs
T23569 924-925 . denotes .
T23570 926-927 -LRB- denotes (
T23571 927-928 NNP denotes A
T23572 928-929 -RRB- denotes )
T23573 930-934 NNS denotes MDMs
T23574 935-939 VBD denotes were
T23575 940-953 VBN denotes pre-incubated
T23576 954-956 IN denotes in
T23577 957-961 NNP denotes RPMI
T23578 962-968 NN denotes medium
T23579 969-979 VBG denotes containing
T23580 980-990 NNS denotes inhibitors
T23581 991-992 -LRB- denotes (
T23582 992-1002 NN denotes Ro-31-8220
T23583 1002-1003 : denotes :
T23584 1004-1005 CD denotes 5
T23585 1006-1008 NNP denotes µM
T23586 1008-1009 , denotes ,
T23587 1010-1017 NNP denotes Gö-6976
T23588 1017-1018 : denotes :
T23589 1019-1020 CD denotes 5
T23590 1021-1023 NNP denotes µM
T23591 1023-1024 , denotes ,
T23592 1025-1033 NNP denotes BAPTA/AM
T23593 1033-1034 : denotes :
T23594 1035-1038 CD denotes 2.5
T23595 1039-1041 NNP denotes µM
T23596 1041-1042 -RRB- denotes )
T23597 1043-1046 IN denotes for
T23598 1047-1049 CD denotes 30
T23599 1050-1057 NNS denotes minutes
T23600 1058-1063 RB denotes prior
T23601 1064-1066 TO denotes to
T23602 1067-1070 DT denotes the
T23603 1071-1079 NN denotes addition
T23604 1080-1082 IN denotes of
T23605 1083-1088 NNP denotes M-CSF
T23606 1088-1089 . denotes .
T23607 1090-1092 IN denotes As
T23608 1093-1094 DT denotes a
T23609 1095-1102 NN denotes control
T23610 1102-1103 , denotes ,
T23611 1104-1113 JJ denotes untreated
T23612 1114-1119 NNS denotes cells
T23613 1120-1124 VBD denotes were
T23614 1125-1134 VBN denotes incubated
T23615 1135-1139 IN denotes with
T23616 1140-1148 NN denotes dimethyl
T23617 1149-1158 NN denotes sulfoxide
T23618 1159-1160 -LRB- denotes (
T23619 1160-1164 NNP denotes DMSO
T23620 1164-1165 -RRB- denotes )
T23621 1165-1166 . denotes .
T23622 1167-1171 NN denotes Cell
T23623 1172-1179 NNS denotes lysates
T23624 1180-1184 VBD denotes were
T23625 1185-1193 VBN denotes resolved
T23626 1194-1196 IN denotes by
T23627 1197-1205 NNP denotes SDS-PAGE
T23628 1206-1209 CC denotes and
T23629 1210-1223 VBN denotes immunoblotted
T23630 1224-1228 IN denotes with
T23631 1229-1237 NN denotes antibody
T23632 1238-1249 VBG denotes recognizing
T23633 1250-1253 DT denotes the
T23634 1254-1260 JJ denotes active
T23635 1261-1268 JJ denotes cleaved
T23636 1269-1273 NN denotes form
T23637 1274-1276 IN denotes of
T23638 1277-1286 JJ denotes caspase-3
T23639 1286-1287 . denotes .
T23640 1288-1291 DT denotes The
T23641 1292-1297 NNS denotes blots
T23642 1298-1302 VBD denotes were
T23643 1303-1312 VBN denotes reblotted
T23644 1313-1317 IN denotes with
T23645 1318-1325 NN denotes β-actin
T23646 1326-1330 IN denotes that
T23647 1331-1337 VBD denotes served
T23648 1338-1340 IN denotes as
T23649 1341-1342 DT denotes a
T23650 1343-1350 VBG denotes loading
T23651 1351-1358 NN denotes control
T23652 1358-1359 . denotes .
T23653 1360-1363 DT denotes The
T23654 1364-1369 NN denotes ratio
T23655 1370-1372 IN denotes of
T23656 1373-1379 JJ denotes active
T23657 1380-1389 JJ denotes caspase-3
T23658 1390-1395 NNS denotes bands
T23659 1396-1397 -LRB- denotes (
T23660 1397-1399 CD denotes 17
T23661 1400-1402 NN denotes kD
T23662 1403-1406 CC denotes and
T23663 1407-1409 CD denotes 19
T23664 1410-1412 NN denotes kD
T23665 1412-1413 -RRB- denotes )
T23666 1414-1416 TO denotes to
T23667 1417-1424 VB denotes β-actin
T23668 1425-1432 NN denotes control
T23669 1433-1436 VBD denotes was
T23670 1437-1447 VBN denotes determined
T23671 1448-1450 IN denotes by
T23672 1451-1463 NN denotes densitometry
T23673 1464-1472 NN denotes analysis
T23674 1473-1474 -LRB- denotes (
T23675 1474-1480 JJ denotes bottom
T23676 1481-1486 NN denotes panel
T23677 1486-1487 -RRB- denotes )
T23678 1487-1488 . denotes .
T23679 1489-1493 NNP denotes Data
T23680 1494-1504 VBZ denotes represents
T23681 1505-1508 DT denotes the
T23682 1509-1513 JJ denotes mean
T23683 1514-1515 NN denotes ±
T23684 1516-1521 NNP denotes S.E.M
T23685 1522-1526 IN denotes from
T23686 1527-1530 CD denotes two
T23687 1531-1542 JJ denotes independent
T23688 1543-1549 NNS denotes donors
T23689 1549-1550 . denotes .
T23690 1551-1552 -LRB- denotes (
T23691 1552-1553 NNP denotes B
T23692 1553-1554 -RRB- denotes )
T23693 1555-1564 NNP denotes Apoptosis
T23694 1565-1567 IN denotes of
T23695 1568-1571 DT denotes the
T23696 1572-1579 VBN denotes treated
T23697 1580-1584 NNS denotes MDMs
T23698 1585-1588 VBD denotes was
T23699 1589-1593 RB denotes also
T23700 1594-1602 VBN denotes measured
T23701 1603-1605 IN denotes by
T23702 1606-1613 NNP denotes Annexin
T23703 1614-1620 NNP denotes V-FITC
T23704 1621-1624 CC denotes and
T23705 1625-1634 NN denotes propidium
T23706 1635-1641 NN denotes iodine
T23707 1642-1643 -LRB- denotes (
T23708 1643-1645 NNP denotes PI
T23709 1645-1646 -RRB- denotes )
T23710 1647-1655 VBG denotes staining
T23711 1656-1659 CC denotes and
T23712 1660-1668 VBN denotes analyzed
T23713 1669-1671 IN denotes by
T23714 1672-1676 NN denotes flow
T23715 1677-1686 NN denotes cytometry
T23716 1686-1687 . denotes .
T23717 1688-1691 DT denotes The
T23718 1692-1702 NN denotes percentage
T23719 1703-1705 IN denotes of
T23720 1706-1715 VBG denotes surviving
T23721 1716-1721 NNS denotes cells
T23722 1722-1723 -LRB- denotes (
T23723 1723-1730 NNP denotes Annexin
T23724 1731-1735 NNP denotes V/PI
T23725 1736-1744 JJ denotes negative
T23726 1744-1745 -RRB- denotes )
T23727 1746-1749 IN denotes for
T23728 1750-1753 DT denotes the
T23729 1754-1759 NNS denotes cells
T23730 1760-1767 VBN denotes treated
T23731 1768-1772 IN denotes with
T23732 1773-1786 NNP denotes vehicle/M-CSF
T23733 1787-1790 VBD denotes was
T23734 1791-1802 RB denotes arbitrarily
T23735 1803-1806 VBN denotes set
T23736 1807-1809 IN denotes as
T23737 1810-1813 CD denotes 100
T23738 1813-1814 . denotes .
T23739 1815-1819 NNP denotes Data
T23740 1820-1825 VBN denotes shown
T23741 1826-1835 VBP denotes represent
T23742 1836-1839 DT denotes the
T23743 1840-1844 JJ denotes mean
T23744 1845-1846 NN denotes ±
T23745 1847-1852 NNP denotes S.E.M
T23746 1853-1857 IN denotes from
T23747 1858-1863 CD denotes three
T23748 1864-1875 JJ denotes independent
T23749 1876-1887 NNS denotes experiments
T23750 1887-1888 . denotes .
T23751 1889-1890 SYM denotes *
T23752 1890-1893 DT denotes The
T23753 1894-1902 NNS denotes p-values
T23754 1903-1905 IN denotes of
T23755 1906-1922 JJ denotes inhibitors/M-CSF
T23756 1923-1931 VBN denotes compared
T23757 1932-1934 TO denotes to
T23758 1935-1948 NNP denotes vehicle/M-CSF
T23759 1949-1953 VBD denotes were
T23760 1954-1955 CD denotes ≤
T23761 1955-1959 CD denotes 0.05
T23762 1959-1960 . denotes .
R4607 T6258 T6291 nsubj NF-κB,hypothesized
R4608 T6259 T6258 cc and,NF-κB
R4609 T6260 T6258 conj PKC,NF-κB
R4610 T6261 T6262 punct (,s
R4611 T6262 T6260 appos s,PKC
R4612 T6263 T6262 punct ),s
R4613 T6264 T6291 advcl Mediate,hypothesized
R4614 T6265 T6266 compound Human,MDM
R4615 T6266 T6267 compound MDM,Survival
R4616 T6267 T6264 dobj Survival,Mediate
R4617 T6268 T6267 prep in,Survival
R4618 T6269 T6268 pobj Response,in
R4619 T6270 T6273 acl to,Since
R4620 T6271 T6272 compound M-CSF,Stimulation
R4621 T6272 T6270 pobj Stimulation,to
R4622 T6273 T6277 mark Since,are
R4623 T6274 T6277 nsubj PKC,are
R4624 T6275 T6274 cc and,PKC
R4625 T6276 T6274 conj NF-κB,PKC
R4626 T6277 T6291 advcl are,hypothesized
R4627 T6278 T6277 acomp critical,are
R4628 T6279 T6278 prep in,critical
R4629 T6280 T6281 compound cell,survival
R4630 T6281 T6279 pobj survival,in
R4631 T6282 T6284 nmod [,]
R4632 T6283 T6284 nummod 37,]
R4633 T6284 T6277 npadvmod ],are
R4634 T6285 T6284 punct ",",]
R4635 T6286 T6288 nmod [,]
R4636 T6287 T6288 nummod 38,]
R4637 T6288 T6284 conj ],]
R4638 T6289 T6291 punct ",",hypothesized
R4639 T6290 T6291 nsubj we,hypothesized
R4640 T6291 T6291 ROOT hypothesized,hypothesized
R4641 T6292 T6294 mark that,promoted
R4642 T6293 T6294 nsubj M-CSF,promoted
R4643 T6294 T6291 ccomp promoted,hypothesized
R4644 T6295 T6296 compound cell,survival
R4645 T6296 T6294 dobj survival,promoted
R4646 T6297 T6294 prep through,promoted
R4647 T6298 T6297 pobj PKC,through
R4648 T6299 T6294 prep in,promoted
R4649 T6300 T6301 amod human,MDMs
R4650 T6301 T6299 pobj MDMs,in
R4651 T6302 T6291 punct .,hypothesized
R4652 T6303 T6304 aux To,detect
R4653 T6304 T6319 advcl detect,analyzed
R4654 T6305 T6304 dobj apoptosis,detect
R4655 T6306 T6305 punct ",",apoptosis
R4656 T6307 T6308 det the,expression
R4657 T6308 T6305 appos expression,apoptosis
R4658 T6309 T6308 prep of,expression
R4659 T6310 T6311 amod cleaved,caspase-3
R4660 T6311 T6309 pobj caspase-3,of
R4661 T6312 T6311 punct ",",caspase-3
R4662 T6313 T6314 det a,marker
R4663 T6314 T6311 appos marker,caspase-3
R4664 T6315 T6314 prep of,marker
R4665 T6316 T6315 pobj apoptosis,of
R4666 T6317 T6319 punct ",",analyzed
R4667 T6318 T6319 auxpass was,analyzed
R4668 T6319 T6319 ROOT analyzed,analyzed
R4669 T6320 T6319 prep in,analyzed
R4670 T6321 T6322 det the,presence
R4671 T6322 T6320 pobj presence,in
R4672 T6323 T6322 cc or,presence
R4673 T6324 T6322 conj absence,presence
R4674 T6325 T6324 prep of,absence
R4675 T6326 T6329 nmod M-CSF,inhibitors
R4676 T6327 T6326 cc and,M-CSF
R4677 T6328 T6326 conj PKC,M-CSF
R4678 T6329 T6325 pobj inhibitors,of
R4679 T6330 T6319 punct .,analyzed
R4680 T6331 T6353 prep In,elevated
R4681 T6332 T6331 pobj MDMs,In
R4682 T6333 T6332 acl pretreated,MDMs
R4683 T6334 T6333 prep with,pretreated
R4684 T6335 T6336 compound PKC,inhibitors
R4685 T6336 T6334 pobj inhibitors,with
R4686 T6337 T6336 punct (,inhibitors
R4687 T6338 T6336 appos Ro-31-8220,inhibitors
R4688 T6339 T6338 punct ",",Ro-31-8220
R4689 T6340 T6338 conj Gö-6976,Ro-31-8220
R4690 T6341 T6340 punct ",",Gö-6976
R4691 T6342 T6340 cc or,Gö-6976
R4692 T6343 T6340 conj BAPTA/AM,Gö-6976
R4693 T6344 T6343 punct ),BAPTA/AM
R4694 T6345 T6333 cc and,pretreated
R4695 T6346 T6333 conj stimulated,pretreated
R4696 T6347 T6346 prep with,stimulated
R4697 T6348 T6347 pobj M-CSF,with
R4698 T6349 T6350 punct ",",cleaved
R4699 T6350 T6351 compound cleaved,caspase-3
R4700 T6351 T6353 nsubjpass caspase-3,elevated
R4701 T6352 T6353 auxpass was,elevated
R4702 T6353 T6353 ROOT elevated,elevated
R4703 T6354 T6353 prep to,elevated
R4704 T6355 T6354 pobj levels,to
R4705 T6356 T6355 prep of,levels
R4706 T6357 T6356 pobj cells,of
R4707 T6358 T6357 acl treated,cells
R4708 T6359 T6358 prep with,treated
R4709 T6360 T6359 pobj vehicle,with
R4710 T6361 T6360 advmod alone,vehicle
R4711 T6362 T6364 punct (,3A
R4712 T6363 T6364 compound Figure,3A
R4713 T6364 T6360 appos 3A,vehicle
R4714 T6365 T6353 punct ),elevated
R4715 T6366 T6353 punct .,elevated
R4716 T6367 T6376 prep In,had
R4717 T6368 T6367 pobj contrast,In
R4718 T6369 T6376 punct ",",had
R4719 T6370 T6376 nsubj cells,had
R4720 T6371 T6370 acl incubated,cells
R4721 T6372 T6371 prep with,incubated
R4722 T6373 T6372 pobj M-CSF,with
R4723 T6374 T6373 cc and,M-CSF
R4724 T6375 T6373 conj vehicle,M-CSF
R4725 T6376 T6376 ROOT had,had
R4726 T6377 T6378 advmod less,cleaved
R4727 T6378 T6379 amod cleaved,caspase-3
R4728 T6379 T6376 dobj caspase-3,had
R4729 T6380 T6379 prep than,caspase-3
R4730 T6381 T6380 pobj cells,than
R4731 T6382 T6381 acl incubated,cells
R4732 T6383 T6382 prep with,incubated
R4733 T6384 T6383 pobj vehicle,with
R4734 T6385 T6382 advmod alone,incubated
R4735 T6386 T6385 cc or,alone
R4736 T6387 T6385 conj M-CSF,alone
R4737 T6388 T6382 prep with,incubated
R4738 T6389 T6390 compound PKC,inhibitors
R4739 T6390 T6388 pobj inhibitors,with
R4740 T6391 T6376 punct .,had
R4741 T6392 T6393 det These,data
R4742 T6393 T6394 nsubj data,supported
R4743 T6394 T6394 ROOT supported,supported
R4744 T6395 T6396 det the,hypothesis
R4745 T6396 T6394 dobj hypothesis,supported
R4746 T6397 T6398 nsubj that,M-CSF-induced
R4747 T6398 T6400 amod M-CSF-induced,activity
R4748 T6399 T6400 amod NF-κB,activity
R4749 T6400 T6402 nsubjpass activity,regulated
R4750 T6401 T6402 auxpass was,regulated
R4751 T6402 T6394 conj regulated,supported
R4752 T6403 T6402 agent by,regulated
R4753 T6404 T6405 amod conventional,PKCs
R4754 T6405 T6403 pobj PKCs,by
R4755 T6406 T6405 punct ",",PKCs
R4756 T6407 T6408 neg not,novel
R4757 T6408 T6409 amod novel,PKCs
R4758 T6409 T6405 appos PKCs,PKCs
R4759 T6410 T6402 punct .,regulated
R4760 T6411 T6412 aux To,confirm
R4761 T6412 T6422 advcl confirm,treated
R4762 T6413 T6416 mark that,decreased
R4763 T6414 T6415 compound PKC,inhibition
R4764 T6415 T6416 nsubj inhibition,decreased
R4765 T6416 T6418 amod decreased,survival
R4766 T6417 T6418 compound cell,survival
R4767 T6418 T6412 dobj survival,confirm
R4768 T6419 T6422 punct ",",treated
R4769 T6420 T6422 nsubjpass cells,treated
R4770 T6421 T6422 auxpass were,treated
R4771 T6422 T6422 ROOT treated,treated
R4772 T6423 T6422 prep with,treated
R4773 T6424 T6423 pobj M-CSF,with
R4774 T6425 T6422 prep in,treated
R4775 T6426 T6427 det the,absence
R4776 T6427 T6425 pobj absence,in
R4777 T6428 T6427 cc or,absence
R4778 T6429 T6427 conj presence,absence
R4779 T6430 T6427 prep of,absence
R4780 T6431 T6432 compound PKC,inhibitors
R4781 T6432 T6430 pobj inhibitors,of
R4782 T6433 T6422 cc and,treated
R4783 T6434 T6436 advmod then,examined
R4784 T6435 T6436 advmod also,examined
R4785 T6436 T6422 conj examined,treated
R4786 T6437 T6436 prep for,examined
R4787 T6438 T6437 pobj apoptosis,for
R4788 T6439 T6436 agent by,examined
R4789 T6440 T6441 compound Annexin,V/PI
R4790 T6441 T6439 pobj V/PI,by
R4791 T6442 T6436 prep staining,examined
R4792 T6443 T6422 punct .,treated
R4793 T6444 T6445 compound PKC,inhibitors
R4794 T6445 T6451 nsubj inhibitors,reduced
R4795 T6446 T6445 prep in,inhibitors
R4796 T6447 T6448 det the,presence
R4797 T6448 T6446 pobj presence,in
R4798 T6449 T6448 prep of,presence
R4799 T6450 T6449 pobj M-CSF,of
R4800 T6451 T6451 ROOT reduced,reduced
R4801 T6452 T6453 det the,number
R4802 T6453 T6451 dobj number,reduced
R4803 T6454 T6453 prep of,number
R4804 T6455 T6456 compound Annexin,V/PI
R4805 T6456 T6458 nmod V/PI,MDMs
R4806 T6457 T6458 amod negative,MDMs
R4807 T6458 T6454 pobj MDMs,of
R4808 T6459 T6451 prep compared,reduced
R4809 T6460 T6459 prep to,compared
R4810 T6461 T6460 pobj cells,to
R4811 T6462 T6461 acl treated,cells
R4812 T6463 T6462 prep with,treated
R4813 T6464 T6463 pobj M-CSF,with
R4814 T6465 T6464 advmod alone,M-CSF
R4815 T6466 T6468 punct (,3B
R4816 T6467 T6468 compound Figure,3B
R4817 T6468 T6464 appos 3B,M-CSF
R4818 T6469 T6451 punct ),reduced
R4819 T6470 T6451 punct .,reduced
R4820 T6471 T6472 det These,observations
R4821 T6472 T6474 nsubj observations,suggested
R4822 T6473 T6474 advmod further,suggested
R4823 T6474 T6474 ROOT suggested,suggested
R4824 T6475 T6479 mark that,promoted
R4825 T6476 T6477 compound MDM,survival
R4826 T6477 T6479 nsubjpass survival,promoted
R4827 T6478 T6479 auxpass is,promoted
R4828 T6479 T6474 ccomp promoted,suggested
R4829 T6480 T6479 agent by,promoted
R4830 T6481 T6480 pobj M-CSF,by
R4831 T6482 T6479 cc and,promoted
R4832 T6483 T6484 advmod critically,involves
R4833 T6484 T6479 conj involves,promoted
R4834 T6485 T6486 amod conventional,PKCs
R4835 T6486 T6484 dobj PKCs,involves
R4836 T6487 T6486 cc and,PKCs
R4837 T6488 T6489 amod NF-κB,activity
R4838 T6489 T6486 conj activity,PKCs
R4839 T6490 T6474 punct .,suggested
R17951 T23560 T23565 nsubj Inhibition,induces
R17952 T23561 T23560 prep of,Inhibition
R17953 T23562 T23561 pobj PKC,of
R17954 T23563 T23562 cc or,PKC
R17955 T23564 T23562 conj NF-κB,PKC
R17956 T23565 T23565 ROOT induces,induces
R17957 T23566 T23565 dobj apoptosis,induces
R17958 T23567 T23565 prep in,induces
R17959 T23568 T23567 pobj MDMs,in
R17960 T23569 T23565 punct .,induces
R17961 T23570 T23575 punct (,pre-incubated
R17962 T23571 T23573 nmod A,MDMs
R17963 T23572 T23573 punct ),MDMs
R17964 T23573 T23575 nsubjpass MDMs,pre-incubated
R17965 T23574 T23575 auxpass were,pre-incubated
R17966 T23575 T23575 ROOT pre-incubated,pre-incubated
R17967 T23576 T23575 prep in,pre-incubated
R17968 T23577 T23578 compound RPMI,medium
R17969 T23578 T23576 pobj medium,in
R17970 T23579 T23578 acl containing,medium
R17971 T23580 T23579 dobj inhibitors,containing
R17972 T23581 T23580 punct (,inhibitors
R17973 T23582 T23580 appos Ro-31-8220,inhibitors
R17974 T23583 T23582 punct :,Ro-31-8220
R17975 T23584 T23585 nummod 5,µM
R17976 T23585 T23582 appos µM,Ro-31-8220
R17977 T23586 T23585 punct ",",µM
R17978 T23587 T23585 appos Gö-6976,µM
R17979 T23588 T23587 punct :,Gö-6976
R17980 T23589 T23590 nummod 5,µM
R17981 T23590 T23587 conj µM,Gö-6976
R17982 T23591 T23590 punct ",",µM
R17983 T23592 T23590 conj BAPTA/AM,µM
R17984 T23593 T23592 punct :,BAPTA/AM
R17985 T23594 T23595 nummod 2.5,µM
R17986 T23595 T23592 appos µM,BAPTA/AM
R17987 T23596 T23592 punct ),BAPTA/AM
R17988 T23597 T23592 prep for,BAPTA/AM
R17989 T23598 T23599 nummod 30,minutes
R17990 T23599 T23597 pobj minutes,for
R17991 T23600 T23587 npadvmod prior,Gö-6976
R17992 T23601 T23600 prep to,prior
R17993 T23602 T23603 det the,addition
R17994 T23603 T23601 pobj addition,to
R17995 T23604 T23603 prep of,addition
R17996 T23605 T23604 pobj M-CSF,of
R17997 T23606 T23575 punct .,pre-incubated
R17998 T23607 T23614 prep As,incubated
R17999 T23608 T23609 det a,control
R18000 T23609 T23607 pobj control,As
R18001 T23610 T23614 punct ",",incubated
R18002 T23611 T23612 amod untreated,cells
R18003 T23612 T23614 nsubjpass cells,incubated
R18004 T23613 T23614 auxpass were,incubated
R18005 T23614 T23614 ROOT incubated,incubated
R18006 T23615 T23614 prep with,incubated
R18007 T23616 T23617 compound dimethyl,sulfoxide
R18008 T23617 T23615 pobj sulfoxide,with
R18009 T23618 T23617 punct (,sulfoxide
R18010 T23619 T23617 appos DMSO,sulfoxide
R18011 T23620 T23617 punct ),sulfoxide
R18012 T23621 T23614 punct .,incubated
R18013 T23622 T23623 compound Cell,lysates
R18014 T23623 T23625 nsubjpass lysates,resolved
R18015 T23624 T23625 auxpass were,resolved
R18016 T23625 T23625 ROOT resolved,resolved
R18017 T23626 T23625 agent by,resolved
R18018 T23627 T23626 pobj SDS-PAGE,by
R18019 T23628 T23625 cc and,resolved
R18020 T23629 T23625 conj immunoblotted,resolved
R18021 T23630 T23629 prep with,immunoblotted
R18022 T23631 T23630 pobj antibody,with
R18023 T23632 T23630 pcomp recognizing,with
R18024 T23633 T23636 det the,form
R18025 T23634 T23636 amod active,form
R18026 T23635 T23636 amod cleaved,form
R18027 T23636 T23632 dobj form,recognizing
R18028 T23637 T23636 prep of,form
R18029 T23638 T23637 pobj caspase-3,of
R18030 T23639 T23625 punct .,resolved
R18031 T23640 T23641 det The,blots
R18032 T23641 T23643 nsubjpass blots,reblotted
R18033 T23642 T23643 auxpass were,reblotted
R18034 T23643 T23643 ROOT reblotted,reblotted
R18035 T23644 T23643 prep with,reblotted
R18036 T23645 T23644 pobj β-actin,with
R18037 T23646 T23647 nsubj that,served
R18038 T23647 T23643 conj served,reblotted
R18039 T23648 T23647 prep as,served
R18040 T23649 T23651 det a,control
R18041 T23650 T23651 compound loading,control
R18042 T23651 T23648 pobj control,as
R18043 T23652 T23643 punct .,reblotted
R18044 T23653 T23654 det The,ratio
R18045 T23654 T23670 nsubjpass ratio,determined
R18046 T23655 T23654 prep of,ratio
R18047 T23656 T23658 amod active,bands
R18048 T23657 T23658 compound caspase-3,bands
R18049 T23658 T23655 pobj bands,of
R18050 T23659 T23658 punct (,bands
R18051 T23660 T23661 nummod 17,kD
R18052 T23661 T23658 appos kD,bands
R18053 T23662 T23661 cc and,kD
R18054 T23663 T23664 nummod 19,kD
R18055 T23664 T23661 conj kD,kD
R18056 T23665 T23664 punct ),kD
R18057 T23666 T23670 prep to,determined
R18058 T23667 T23668 compound β-actin,control
R18059 T23668 T23666 pobj control,to
R18060 T23669 T23670 auxpass was,determined
R18061 T23670 T23670 ROOT determined,determined
R18062 T23671 T23670 agent by,determined
R18063 T23672 T23673 amod densitometry,analysis
R18064 T23673 T23671 pobj analysis,by
R18065 T23674 T23676 punct (,panel
R18066 T23675 T23676 amod bottom,panel
R18067 T23676 T23673 appos panel,analysis
R18068 T23677 T23670 punct ),determined
R18069 T23678 T23670 punct .,determined
R18070 T23679 T23680 nsubj Data,represents
R18071 T23680 T23680 ROOT represents,represents
R18072 T23681 T23684 det the,S.E.M
R18073 T23682 T23684 amod mean,S.E.M
R18074 T23683 T23684 compound ±,S.E.M
R18075 T23684 T23680 dobj S.E.M,represents
R18076 T23685 T23684 prep from,S.E.M
R18077 T23686 T23688 nummod two,donors
R18078 T23687 T23688 amod independent,donors
R18079 T23688 T23685 pobj donors,from
R18080 T23689 T23680 punct .,represents
R18081 T23690 T23693 punct (,Apoptosis
R18082 T23691 T23693 nmod B,Apoptosis
R18083 T23692 T23693 punct ),Apoptosis
R18084 T23693 T23700 nsubjpass Apoptosis,measured
R18085 T23694 T23693 prep of,Apoptosis
R18086 T23695 T23697 det the,MDMs
R18087 T23696 T23697 amod treated,MDMs
R18088 T23697 T23694 pobj MDMs,of
R18089 T23698 T23700 auxpass was,measured
R18090 T23699 T23700 advmod also,measured
R18091 T23700 T23700 ROOT measured,measured
R18092 T23701 T23700 agent by,measured
R18093 T23702 T23703 compound Annexin,V-FITC
R18094 T23703 T23701 pobj V-FITC,by
R18095 T23704 T23703 cc and,V-FITC
R18096 T23705 T23706 compound propidium,iodine
R18097 T23706 T23703 conj iodine,V-FITC
R18098 T23707 T23708 punct (,PI
R18099 T23708 T23706 appos PI,iodine
R18100 T23709 T23706 punct ),iodine
R18101 T23710 T23700 advcl staining,measured
R18102 T23711 T23700 cc and,measured
R18103 T23712 T23700 conj analyzed,measured
R18104 T23713 T23712 agent by,analyzed
R18105 T23714 T23715 compound flow,cytometry
R18106 T23715 T23713 pobj cytometry,by
R18107 T23716 T23700 punct .,measured
R18108 T23717 T23718 det The,percentage
R18109 T23718 T23735 nsubjpass percentage,set
R18110 T23719 T23718 prep of,percentage
R18111 T23720 T23721 amod surviving,cells
R18112 T23721 T23719 pobj cells,of
R18113 T23722 T23718 punct (,percentage
R18114 T23723 T23724 compound Annexin,V/PI
R18115 T23724 T23718 appos V/PI,percentage
R18116 T23725 T23724 amod negative,V/PI
R18117 T23726 T23718 punct ),percentage
R18118 T23727 T23718 prep for,percentage
R18119 T23728 T23729 det the,cells
R18120 T23729 T23727 pobj cells,for
R18121 T23730 T23729 acl treated,cells
R18122 T23731 T23730 prep with,treated
R18123 T23732 T23731 pobj vehicle/M-CSF,with
R18124 T23733 T23735 auxpass was,set
R18125 T23734 T23735 advmod arbitrarily,set
R18126 T23735 T23735 ROOT set,set
R18127 T23736 T23735 prep as,set
R18128 T23737 T23736 pobj 100,as
R18129 T23738 T23735 punct .,set
R18130 T23739 T23741 nsubj Data,represent
R18131 T23740 T23739 acl shown,Data
R18132 T23741 T23741 ROOT represent,represent
R18133 T23742 T23745 det the,S.E.M
R18134 T23743 T23745 amod mean,S.E.M
R18135 T23744 T23745 compound ±,S.E.M
R18136 T23745 T23741 dobj S.E.M,represent
R18137 T23746 T23741 prep from,represent
R18138 T23747 T23749 nummod three,experiments
R18139 T23748 T23749 amod independent,experiments
R18140 T23749 T23746 pobj experiments,from
R18141 T23750 T23741 punct .,represent
R18142 T23751 T23751 ROOT *,*
R18143 T23752 T23753 det The,p-values
R18144 T23753 T23756 nsubj p-values,compared
R18145 T23754 T23753 prep of,p-values
R18146 T23755 T23754 pobj inhibitors/M-CSF,of
R18147 T23756 T23756 ROOT compared,compared
R18148 T23757 T23756 prep to,compared
R18149 T23758 T23757 pobj vehicle/M-CSF,to
R18150 T23759 T23756 auxpass were,compared
R18151 T23760 T23761 compound ≤,0.05
R18152 T23761 T23759 attr 0.05,were
R18153 T23762 T23756 punct .,compared

test2

Id Subject Object Predicate Lexical cue
T6229 59-64 Protein denotes M-CSF
T6230 160-165 Protein denotes M-CSF
T6231 241-251 Gene_expression denotes expression
T6232 263-272 Protein denotes caspase-3
T6233 340-345 Protein denotes M-CSF
T6234 460-465 Protein denotes M-CSF
T6235 467-474 Positive_regulation denotes cleaved
T6236 475-484 Protein denotes caspase-3
T6237 489-497 Positive_regulation denotes elevated
T6238 591-596 Protein denotes M-CSF
T6239 626-635 Protein denotes caspase-3
T6240 679-684 Protein denotes M-CSF
T6241 747-752 Protein denotes M-CSF
T6242 2043-2048 Protein denotes M-CSF
T6243 2134-2143 Protein denotes Annexin V
T6244 2191-2196 Protein denotes M-CSF
T6245 2197-2204 Negative_regulation denotes reduced
T6246 2219-2228 Protein denotes Annexin V
T6247 2232-2240 Negative_regulation denotes negative
T6248 2277-2282 Protein denotes M-CSF
T6249 2372-2377 Protein denotes M-CSF
T23538 1083-1088 Protein denotes M-CSF
T23539 1318-1325 Protein denotes β-actin
T23540 1380-1389 Protein denotes caspase-3
T23541 1417-1424 Protein denotes β-actin
T23542 1606-1615 Protein denotes Annexin V
T23543 1723-1732 Protein denotes Annexin V
T23544 1736-1744 Negative_regulation denotes negative
T23545 1781-1786 Protein denotes M-CSF
T23546 1917-1922 Protein denotes M-CSF
T23547 1943-1948 Protein denotes M-CSF
R4602 T6232 T6231 themeOf caspase-3,expression
R4603 T6236 T6235 themeOf caspase-3,cleaved
R4604 T6244 T6245 causeOf M-CSF,reduced
R4605 T6246 T6247 themeOf Annexin V,negative
R4606 T6247 T6245 themeOf negative,reduced
R17950 T23543 T23544 themeOf Annexin V,negative